ANNUAL REPORT
2017
Lives unaffected by cystic fibrosis
CYSTIC FIBROSIS QUEENSLAND IS ON A MISSION TO PROVIDE ALL OF OUR MEMBERS WITH A NEBULISER. PEOPLE WITH CYSTIC FIBROSIS TAKE UP TO A WHEELIE BIN OF TABLETS PER YEAR.
# Table of Contents

- WHAT IS CYSTIC FIBROSIS? ................................................................. 5  
- HOW DO YOU GET CYSTIC FIBROSIS? ........................................ 7  
- HOW IS CYSTIC FIBROSIS TREATED? .......................................... 7  
- HOW IS CYSTIC FIBROSIS DIAGNOSED? ....................................... 9  
- OUR MISSION .................................................................................. 11  
- OUR HISTORY .................................................................................. 13  
- OUR HISTORY - A TIMELINE .......................................................... 16-17  
- RESPONDING TO THE NEEDS OF OUR MEMBERS ...................... 19  
- A MESSAGE FROM OUR QUEENSLAND PATRON ....................... 23  
- OUR NORTHERN TERRITORY PATRON’S MESSAGE ................... 25  
- CHIEF EXECUTIVE OFFICER’S REPORT ....................................... 27  
- PRESIDENT’S REPORT .................................................................... 29  
- THE FIVE PILLARS ......................................................................... 31  
- OUR PEOPLE ................................................................................... 33  
- CYSTIC FIBROSIS QUEENSLAND MEMBERS .............................. 35  
- STRUCTURE AND MANAGEMENT .................................................. 37  
- HOW WE ARE MAKING A DIFFERENCE ....................................... 41  
- REVENUE AND EXPENDITURE FOR 2017 .................................... 49  
- OUR COMMUNITY PROJECTS ....................................................... 53  
- DIRECTORS’ REPORT .................................................................... 57  
- TREASURER’S REPORT .................................................................. 63  
- AUDITOR’S INDEPENDENCE DECLARATION ................................. 64  
- STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME ................................................................. 65  
- STATEMENT OF FINANCIAL POSITION ....................................... 66  
- STATEMENT OF CHANGES IN EQUITY ....................................... 67  
- STATEMENT OF CASH FLOWS .................................................... 68  
- NOTES TO THE FINANCIAL STATEMENTS .................................. 69  
- DIRECTORS’ DECLARATION ........................................................... 79  
- INDEPENDENT AUDITOR’S REPORT ............................................ 81  
- LOOKING TO THE FUTURE ............................................................ 93  
- CYSTIC FIBROSIS QUEENSLAND PRIORITIES ............................ 95  
- THANK YOU TO OUR SPONSORS ............................................... 97
CYSTIC FIBROSIS QUEENSLAND PROVIDES SUPPORT, SERVICES AND HOPE TO THOSE FIGHTING CYSTIC FIBROSIS.

OUR COMMUNITY HELPS US TO SHAPE THE SUPPORT AND SERVICES WE PROVIDE.
WHAT IS CYSTIC FIBROSIS?

Cystic fibrosis primarily affects the lungs and digestive systems due to an exocrine malfunction that is responsible for producing saliva, sweat, tears and mucus. There is currently no cure.

People with cystic fibrosis develop an abnormal amount of excessively thick and sticky mucus within the lungs, airways and the digestive system. This causes impairment of the digestive functions of the pancreas and traps bacteria in the lungs resulting in recurrent infections and leading to irreversible damage. Lung failure is the major cause of death for someone with cystic fibrosis.

From birth, a person with cystic fibrosis undergoes constant medical treatments and physiotherapy.
Life with cystic fibrosis is socially isolating. Due to infection control, people with cystic fibrosis cannot have personal contact with each other.

Cystic fibrosis is a chronic genetic illness there is no cure.
HOW DO YOU GET CYSTIC FIBROSIS?

You cannot catch cystic fibrosis. The cystic fibrosis gene is inherited from both parents and it can skip generations. It is autosomal recessive meaning that it occurs equally in males and females. In Australia, one in 2500 babies are born with cystic fibrosis, that’s one every four days. On average one in 25 people carry the cystic fibrosis gene and most are unaware that they are carriers. Because carriers of cystic fibrosis are unaffected and therefore show no symptoms, it is hard for them to appreciate that cystic fibrosis may be a real risk.

Any one of us could be a carrier and not know it. There are about one million unaware carriers in Australia. In Tasmania, one in 20 people carry the cystic fibrosis gene. This is the second highest rate in the world behind Ireland.

HOW IS CYSTIC FIBROSIS TREATED?

Management and treatment of cystic fibrosis is lifelong, ongoing and relentless. A person with cystic fibrosis may consume up to 80 capsules daily to help digest food and may need to do up to four hours of airway clearance physiotherapy each day. It is important for people with cystic fibrosis to visit a cystic fibrosis treatment centre several times each year so their progress can be monitored.

A person living with cystic fibrosis takes up to one wheelie bin full of medication each year.

Treatment generally involves:

- Intensive daily physiotherapy to clear the lungs
- Enzyme replacement capsules with food to aid digestion
- Antibiotic therapy to treat lung infections
- Aerosol mist inhalations via a nebuliser to help open the airways
- Salt and vitamin supplements
- A nutritious diet that is also high calorie, high salt and high fat
- Exercise - important to help clear the airways and build core strength.

A person living with cystic fibrosis must do all of this while continuing their normal daily activities like going to school or work.

People with cystic fibrosis are not encouraged to socialise with each other. The risk of cross-infection and exacerbation of lung conditions is too great. That means cystic fibrosis can be a lonely existence because people with cystic fibrosis cannot personally interact to share experiences and offer support.
CYSTIC FIBROSIS IS A COMPLEX GENETIC DISEASE THAT CAUSES MALFUNCTIONING IN THE LUNGS, PANCREAS AND THE BODY’S INTERNAL COOLING SYSTEM.

CYSTIC FIBROSIS CAME INTO THE HUMAN GENOME ABOUT 5 000 YEARS AGO.
Since 1986, all newborns have been subject to a heel prick test. This test is used to screen for a number of conditions, one of which is an indicator for cystic fibrosis. Diagnosis may also result after a baby is born with obvious cystic fibrosis symptoms such as bowel blockage or failure to ‘thrive’. The heel prick test does not detect cystic fibrosis in everyone and the sweat test continues to be the definitive test, as high levels of salt in perspiration is extremely common amongst those with cystic fibrosis.

CARRIER SCREENING

Cystic fibrosis came into the human genome about 5000 years ago and it has survived and spread. Today there is thought to be almost 2000 mutations that lead to cystic fibrosis, some of which are particular to individual families. At the other extreme, one mutation, Delta F508, is present in some 72% of all cases worldwide.

Carriers are symptomless and live normal lives. They are overwhelmingly unaware of their cystic fibrosis carrier status. Yet they have every chance of passing on the gene to the next generation and that generation to the next and so on – it is only a matter of time before a member of the carrier’s family is born with cystic fibrosis.

WHAT HAPPENS WHEN TWO CARRIERS HAVE CHILDREN?

Two carrier parents have a 25% chance of having a child with cystic fibrosis with each pregnancy.

- 1 in 4 chance the child will have cystic fibrosis
- 1 in 4 chance the child will not have cystic fibrosis (will not have a copy of or be a carrier of the cystic fibrosis gene)
- 2 in 4 chance the child will be a carrier of cystic fibrosis (having one copy of the cystic fibrosis cystic fibrosis gene)

Where an infant receives the cystic fibrosis gene from just one parent, he or she will not be born with cystic fibrosis, but be a lifelong symptomless carrier of the cystic fibrosis gene like his or her parents.
SECTION 1

AN OVERVIEW OF CYSTIC FIBROSIS QUEENSLAND

OUR VISION: LIVES UNAFFECTED BY CYSTIC FIBROSIS.
OUR MISSION

To support Queenslanders and Northern Territorians with cystic fibrosis and their families through education, support, services and advocacy.

- To be relevant to our community
- To work collaboratively and advocate for our community
- To be effective in the work we do for our community
- To be respectful of our community, our stakeholders and each other.
IN MARCH 1971, QUEENSLAND AND NEW SOUTH WALES CYSTIC FIBROSIS ASSOCIATIONS AGREED TO WORK TOGETHER.
Cystic Fibrosis Queensland registered as the Australian Cystic Fibrosis Association July 1960. The first meeting took place in the inner-city Brisbane suburb of Annerley. Annual membership was set at one pound and the main task was fundraising appeals; 90% of funds raised were to support research and 10% to provide education to sufferers and their families to manage the chronic illness.

The first Patron was Sir Josiah Francis, Liberal Federal MP who served until his death in 1964. Senator Dame Annabelle Rankin OBE, Liberal Federal MP, was unanimously elected as his replacement due to her advocacy and support for the sector during parliamentary sittings.

In March 1971, Queensland and New South Wales Cystic Fibrosis Associations agreed to work together, with the objective of conducting international liaison, nurturing new state organisations and providing a central body that would promote cystic fibrosis at a national level. It was an important first step on a quest to alleviate the suffering of children afflicted with cystic fibrosis and search for better ways to cope with what was then a largely uncharted disease.

The Association’s first President was Professor J Beveridge. He was supported by a Vice President, Mrs J Robertson and Hon Sec/Treasurer Mr I Beatty. A medical and scientific advisory panel was also formed, and the first convenor of this group was Dr J Brown.

In 1983, the six state and territory organisations formed a national body called Australian Cystic Fibrosis Associations Federation Incorporated. In 1998 it was renamed Cystic Fibrosis Australia Incorporated. Cystic Fibrosis Australia was established to facilitate and promote the provision of optimal
IN 1988, THE FIRST INTERNATIONAL CYSTIC FIBROSIS CONFERENCE IN THE SOUTHERN HEMISPHERE WAS HELD IN SYDNEY.
care to all people affected by cystic fibrosis and ensure the best possible quality of life. At the end of April 2003 Cystic Fibrosis Australia became a company Limited by Guarantee.

The national organisation assists the member organisations achieve common objectives in advocacy, funding and collaboration. Cystic Fibrosis Australia develops and manages national clinical improvement programs, consumer engagement initiatives and conducts cystic fibrosis research throughout Australia into the cause, treatments and an eventual cure for cystic fibrosis. The Australian Cystic Fibrosis Research Trust operating within the Cystic Fibrosis Australia corporate structure has supported more than 30 projects valued at more than $3,000,000.

In 1996, work began on developing the Australian Cystic Fibrosis Data Registry and the working model was released in 1998. Cystic Fibrosis Australia is responsible for the funding (through financial contributions from the States and Territories) and data custodianship of the Australian Cystic Fibrosis Data Registry. On 1 September 2016, the Monash Data Registry Centre became the new management company for the Registry. The future of the Australian Cystic Fibrosis Data Registry is in great hands. The move has enabled digital and clinical development to be undertaken.

In 1988, the first International Cystic Fibrosis Conference in the southern hemisphere was held in Sydney and in 1994 Cystic Fibrosis Australia organised the inaugural Australasian Cystic Fibrosis Conference. This allowed the medical, scientific, allied health and lay communities to come together for knowledge gathering, information sharing and understanding of new trends from overseas. The 12th Australasian Cystic Fibrosis Conference was held in Melbourne, 5 - 8 August 2017 and the 2019 Australasian Cystic Fibrosis Conference will be held in Perth.

In 2001, under a new constitution, the Cystic Fibrosis Association of Queensland changed its name to Cystic Fibrosis Queensland Limited to better reflect the Federation model. This constitution principally remains in place today.

In 2018, Cystic Fibrosis Queensland will provide support, services and advocacy for cystic fibrosis sufferers living in the Northern Territory, in response to growing numbers. To mark the event, the Northern Territory Administrator, The Honourable Vicki O’Halloran OM accepted our request to be our Northern Territory Cystic Fibrosis Queensland Patron.

His Excellency, the Governor of Queensland the Honourable Paul de Jersey AC, QC, remains the Patron of Cystic Fibrosis Queensland, and together they support the advocacy undertaken by the Chief Executive Officer and the Cystic Fibrosis Queensland Board.
1960
Cystic Fibrosis Queensland registered as the Australian Cystic Fibrosis Association.

1971
Queensland and New South Wales Cystic Fibrosis Associations agreed to work together.

1983
The six state and territory organisations formed a national body called Australian Cystic Fibrosis Associations Federation Incorporated.

1988
The first International Cystic Fibrosis Conference in the southern hemisphere was held in Sydney.

1994
Cystic Fibrosis Australia organised the inaugural Australasian Cystic Fibrosis Conference.

1996
Work began on developing the Australian Cystic Fibrosis Data Registry and the working model was released in 1998.

2016
The Monash Data Registry Centre became the new management company for the Registry.

2001
Under a new constitution, the Cystic Fibrosis Association of Queensland changed its name to Cystic Fibrosis Queensland Limited.

2003
Cystic Fibrosis Australia became a company Limited by Guarantee.

1999
Rose Cottage was purchased – home away from home for rural, regional and remote members.

2017
The 12th Australasian Cystic Fibrosis Conference was held in Melbourne.
OUR HISTORY - A TIMELINE

1960
Cystic Fibrosis Queensland registered as the Australian Cystic Fibrosis Association.

1971
Queensland and New South Wales Cystic Fibrosis Associations agreed to work together.

1983
The six state and territory organisations formed a national body called Australian Cystic Fibrosis Associations Federation Incorporated.

1994
Cystic Fibrosis Australia organised the inaugural Australasian Cystic Fibrosis Conference.

1996
Work began on developing the Australian Cystic Fibrosis Data Registry and the working model was released in 1998.

1998
Cystic Fibrosis Associations Federation Incorporated was renamed Cystic Fibrosis Australia Incorporated.

1999
Rose Cottage was purchased - home away from home for rural, regional and remote members.

1999
Under a new constitution, the Cystic Fibrosis Association of Queensland changed its name to Cystic Fibrosis Queensland Limited.

2001

2003
Cystic Fibrosis Australia became a company Limited by Guarantee.

2003

2001

2016
The Monash Data Registry Centre became the new management company for the Registry.

2017
The 12th Australasian Cystic Fibrosis Conference was held in Melbourne.

2017

2019

2018
Cystic Fibrosis Queensland will provide support, services and advocacy for cystic fibrosis sufferers living in the Northern Territory.

2019
Australasian Cystic Fibrosis Conference will be held in Perth.
2020 WILL BE OUR 60TH ANNIVERSARY OF PROVIDING SUPPORT, SERVICES AND HOPE TO THOSE FIGHTING CYSTIC FIBROSIS.
Ten years ago, Cystic Fibrosis Queensland supported and advocated for approximately 730 cystic fibrosis sufferers and their families. While there is no cure for cystic fibrosis, education and an increased understanding of the disease itself, including the impact of diet, exercise, airway clearance and infection control has extended the lives of many sufferers living with cystic fibrosis. As a consequence, the number of people requiring our help, both today and projected, has increased.

**STRATEGIC VISION FOR 2020**

At the end of 2016 a new Chief Executive Officer Petrina Fraccaro, was recruited to transform the organisation and create robust, sustainable income streams to meet the financial pressure placed on Cystic Fibrosis Queensland to deliver support and services to the increasing number of sufferers. With the support of the Chair and Board, a Strategic Plan was created to provide the vision for 2020 - the year that will mark 60 years of Cystic Fibrosis Queensland providing support, services and hope to people fighting cystic fibrosis.

**CYSTIC FIBROSIS QUEENSLAND AND QUEENSLAND HEALTH**

Cystic Fibrosis Queensland works hard to complement the support and services delivered by Queensland Health. A shared goal with clinicians is adherence to patient health management plans. Our physical activity and hospital parking subsidies ensure people maintain exercise and regular appointments. As there is no Queensland Health funding for hospital prescribed airway clearance equipment. Cystic Fibrosis Queensland raises necessary funds to purchase this life-giving equipment, as we know how important lung clearance is to quality of life for a cystic fibrosis sufferer.

**SUBLIDES FOR NEBULISERS**

This year also saw Cystic Fibrosis Queensland introduce subsidies for nebulisers. People with cystic fibrosis can spend up to two hours each day, twice a day taking medication.

A nebuliser reduces this from two hours to 20 minutes. This equates to 610 hours of reduced treatment time a year, or 25 days for someone living with cystic fibrosis.
THE SEARCH FOR A CURE CONTINUES AND TOGETHER WE CAN ALL LOOK FORWARD TO A FUTURE OF LIVING LIVES UNAFFECTED BY CYSTIC FIBROSIS.

CYSTIC FIBROSIS QUEENSLAND IS ENSURING THAT ALL CYSTIC FIBROSIS SUFFERERS LIVE EACH DAY TO THE FULLEST
DIVERSIFIED INCOME STREAMS

To meet the growing demand for support and services, Cystic Fibrosis Queensland diversified its income streams by adding to its staff a specialist in grants, bequests and workplace giving, and creating a social enterprise at the Cystic Fibrosis Queensland Bookshop, delivering fee for service retail training and hosting ‘Work for the Dole’ volunteers. The organisation continues to seek creative and innovative ways to generate and secure income.

HUMAN RESOURCES

A small team of highly skilled staff operates the organisation. By the end of 2017, the full-time equivalent (FTE) was reduced from 9.5 to 6.75, lowering overheads and operational costs. Staff are supported by university internships to increase capacity. In 2017, staff delivered outcomes to meet the strategic plan and key performance indicators set by the Cystic Fibrosis Queensland Board.

Creating lives unaffected by cystic fibrosis - more than a search for a cure - Cystic Fibrosis Queensland is ensuring that all cystic fibrosis sufferers live each day to the fullest.

ADVOCACY

The role of Cystic Fibrosis Queensland is to provide support, services and advocate on behalf of cystic fibrosis sufferers and their families. There is no designated State or Federal Government funding for research or treatment of cystic fibrosis. Cystic fibrosis is a chronic illness and not a disability. Sufferers are not included in the National Disability Insurance Scheme and there is no provision for Disability Pensions. Cystic Fibrosis Queensland focuses on keeping our members well and healthy - reducing both their frequency and duration of hospital stays.

Cystic Fibrosis Queensland advocates for our members with politicians and Queensland Health employees. We believe that at a minimum, cystic fibrosis sufferers should be given the same access to government support and services provided to other Queenslanders living with life shortening health conditions. On our members’ behalf, we also promote to these sectors the importance of infection control, especially during periods of hospitalisation.

The search for a cure continues and together we can all look forward to a future of living lives unaffected by cystic fibrosis.
I AM PLEASED TO SEE CYSTIC FIBROSIS QUEENSLAND RISING TO THIS CHALLENGE, AND ENCOURAGE THE ORGANISATION’S FUNDRAISING EFFORTS AND THEIR FAMILIES.

EXTENDING LIFE EXPECTANCY AND IMPROVING THE QUALITY OF LIFE FOR PEOPLE WITH CYSTIC FIBROSIS.
I am delighted to provide this message for the 2017 Annual Report of Cystic Fibrosis Queensland.

This report captures a busy and purposeful year for Cystic Fibrosis Queensland, buoyed by advances in the management of the disease which are extending life expectancy and improving the quality of life for people with Cystic Fibrosis. Ten years ago, a person with Cystic Fibrosis had a life expectancy of only 18 years. Today, that life expectancy has risen to almost 38 years. This remarkable improvement gives hope to people with Cystic Fibrosis and their families. Research is continuing into interventions that promise to further extend life expectancy, and hopefully find a cure for this devastating disease. Today in Queensland, there are more adults than children living with Cystic Fibrosis. This is an immensely positive development that is transforming the work of Cystic Fibrosis Queensland, as it extends its efforts beyond supporting children and their families to providing effective support and services for adults living with Cystic Fibrosis. I am pleased to see Cystic Fibrosis Queensland rising to this challenge, and encourage the organisation’s fundraising efforts as well as its advocacy on behalf of people living with Cystic Fibrosis and their families. As Patron of Cystic Fibrosis Queensland, I commend this report to the widest possible readership.

HIS EXCELLENCY THE HONOURABLE PAUL DE JERSEY AC GOVERNOR OF QUEENSLAND.
IT IS THEREFORE IMPORTANT, NOW MORE THAN EVER, TO INCREASE RECOGNITION OF SERVICES AND SUPPORT FOR TERRITORIANS.

I WAS INCREDIBLY IMPRESSED BY THE ENERGY, DEPTH OF KNOWLEDGE AND COMMITMENT THAT WAS ON DISPLAY.
It is a great honour to be the first Northern Territory Patron for Cystic Fibrosis Queensland members living in the Territory. I first met your CEO for Queensland, Petrina Fraccaro, at the Cystic Fibrosis Australia Patron Awards in 2017. I was incredibly impressed by the energy, depth of knowledge and commitment that was on display at this event. It was clear to me that everyone – from senior management through to volunteers and interns – has great passion and purpose for providing practical support to Australians with Cystic Fibrosis and their families. I understand that the number of people living with Cystic Fibrosis in the Northern Territory is growing. Individuals are cared for at Royal Darwin Hospital but must travel to Brisbane at certain times for treatments. It is therefore important, now more than ever, to increase recognition of services and support for Territorians. Plans are underway for the Northern Territory’s first morning tea to be held at Government House in early May. This will coincide with the 65 Roses campaign and will be a wonderful opportunity to meet with Territorians and their families affected by Cystic Fibrosis. I am very much looking forward to my role as Patron. My best wishes to you all for 2018.

HER HONOUR THE HONOURABLE VICKI O’HALLORAN AM ADMINISTRATOR OF THE NORTHERN TERRITORY.
Cystic Fibrosis Queensland also provides direct funding to Cystic Fibrosis Australia to produce the data registry for Queensland and the Northern Territory.

We are especially proud of our efforts to contribute to research. Cystic Fibrosis Queensland has supported the Australian Cystic Fibrosis Research Trust.
Cystic Fibrosis Queensland is a not-for-profit charity dedicated to providing high quality support and services, funding for research and advocacy on behalf of the increasing number of people living with cystic fibrosis.

In order to achieve our vision of ‘lives unaffected by cystic fibrosis’ we need to ensure that Cystic Fibrosis Queensland has the resources and capacity to deliver practical support programs and services to the cystic fibrosis community across Queensland, the Northern Territory and parts of northern New South Wales.

Many of these initiatives are included in this Annual Report, and while we can’t produce a cure for cystic fibrosis ourselves, we can provide vital support and services that make day-to-day life easier for our clients and their families, friends and loved ones touched by this chronic condition.

It is essential that there is wider community awareness of the challenges faced by cystic fibrosis sufferers, and those who care for them, remain at the forefront of our efforts. The challenges include: financial, emotional and physical. Cystic fibrosis is the most common, life-shortening genetic condition in Australia. Despite Queensland having per-capita the highest number of people with cystic fibrosis in Australia, not a great deal is known about this chronic illness.

By providing information and raising awareness, we not only relieve parents, carers and families of much of the burden of explaining cystic fibrosis’ complexities, but also do more to highlight the urgent need for funding for our programs.

State and Federal Government provide no designated funding for Cystic Fibrosis Queensland support and services. We rely on generous donations from community fund raisers, public and private donors, corporate sponsors and service clubs to meet our financial needs. Cystic Fibrosis Queensland’s success is underpinned by our dedicated volunteers, interns and Board. These people work tirelessly for our cause and are generous with both their time and spirit.

We are especially proud of our efforts to contribute to research. Cystic Fibrosis Queensland has supported the Australian Cystic Fibrosis Research Trust by working with Cystic Fibrosis Research Limited to fund Innovation Grants in 2018. Cystic Fibrosis Queensland also provides direct funding to Cystic Fibrosis Australia to produce the Data Registry for Queensland and the Northern Territory.

Ten years ago, when the average life span of a cystic fibrosis sufferer was 18 years, it was considered a childhood disease. Today, there are more adults living with cystic fibrosis than children. The average life span of a child born today with cystic fibrosis is just short of 38 years. While there is no cure, we have extended life through better management and improved knowledge of the disease, infection control, diet, exercise and medication, which all play a vital role in the health and wellness of a sufferer.

As a Federation member, and with a position on the Cystic Fibrosis Australia Board, Cystic Fibrosis Queensland continues to work collaboratively with the Federation, State and Territory members to raise the profile and awareness for our cause Australia-wide.

Together we are working to meet the changing needs of our community.

PETRINA FRACCARO
I AM PROUD OF CYSTIC FIBROSIS QUEENSLAND AND THE ROLE IT PLAYS IN ENSURING WE CREATE TODAY, A BETTER TOMORROW, FOR CYSTIC FIBROSIS SUFFERERS.

CYSTIC FIBROSIS QUEENSLAND WILL CONTINUE TO WORK COLLABORATIVELY WITH CLINICIANS TO COMPLEMENT THE SERVICES PROVIDED BY QUEENSLAND HEALTH AND TO AVOID DUPLICATION.
On behalf of the Board, I am pleased to introduce the Cystic Fibrosis Queensland 2017 Annual Report. As a former Chief Financial Officer and qualified corporate accountant, I was very pleased in 2016 to be appointed as Board Chair. As a cystic fibrosis grandmother, I also have a stake in ensuring that the charity is professionally run and financially viable.

The Board and staff at Cystic Fibrosis Queensland are committed to our mission – to be relevant to our community, to work collaboratively with stakeholders and to advocate effectively and, most importantly of all, to remain respectful to the community we support.

It has been a productive year, and in 2017, Cystic Fibrosis Queensland has performed well. The current CEO, Petrina Fraccaro, has been in the position for 12 months and has built a small team of committed staff focused on raising funds and awareness of our cause.

On behalf of the Board, I would like to congratulate all Cystic Fibrosis Queensland staff, volunteers and interns for a job well done.

Throughout 2017, the Board continued with its focus on long-term financial sustainability with the organisation returning to a strong revenue position and a surplus by the end of financial year.

The Board remains focused on strong financial outcomes for Cystic Fibrosis Queensland. All staff have key performance indicators embedded in their position descriptions and regular reviews conducted against their targets. Skilled staff are now employed in grants, community engagement and fundraising, business development and marketing, and events. There are no administration staff, reducing overheads and keeping the organisation lean.

Closure of the Salisbury Cystic Fibrosis Queensland Bookshop, in late 2016, and the amalgamation into the Cystic Fibrosis Queensland Bookshop based at Nundah has been a financial success. While revenue originally decreased it now meets expectations. More importantly, there has been a reduction in overheads and an increase in profit due to the economies of scale.

Cystic Fibrosis Queensland will continue to work collaboratively with clinicians to complement the services provided by Queensland Health and to avoid duplication.

I am proud of Cystic Fibrosis Queensland and the role it plays in ensuring we create today, a better tomorrow, for cystic fibrosis sufferers.

MARGARET WALKER
ACHIEVEMENTS AGAINST OUR STRATEGIC PLAN:
2017 – 2020
THE FIVE PILLARS

COLLABORATION AND ADVOCACY

CF CAN members recruited, trained and participated in media, political meetings and engaged in public speaking.

NT is now included in our services and support model – ensuring more people with cystic fibrosis receive the support that they need.

We worked with like minded charities to deliver education and knowledge about the disease and management of cystic fibrosis.

We participated in hospital stakeholder meetings and forums - continually seeking to enhance and extend the services provided by government.

RESEARCH

We provided much-needed funds for the data registry. Cystic Fibrosis Research Limited is funding an Australian Cystic Fibrosis Research Trust Innovation Grant early 2018.

SERVICE AND FUNDING

The person living with cystic fibrosis is the focal point of primary support and services. Positive Profiles represented our community - living lives unaffected by cystic fibrosis. In 2017, almost 50% of revenue delivered services, support and research outcomes.

EDUCATION AND KNOWLEDGE SHARING

Our services team was visible at cystic fibrosis clinics raising profile and awareness of support and services. They promoted the educational tools CF Consumer Connect, CF SMART and CF HUB to members and community.

Cystic Fibrosis Queensland Forum and Expo informed and educated our community and provided psychosocial support.

VISIBILITY - LET’S GET FAMOUS

We engaged directly with politicians, stakeholders and media to raise the profile of our cause. Infection control remains at the forefront of our advocacy.

65 Roses Month of May campaign reached out to the media - gaining television, radio and print coverage.

CF CAN and CF Ambassadors spoke on behalf of our cause and organisation across the state - raising awareness and funds for all cystic fibrosis sufferers.
ALL CYSTIC FIBROSIS QUEENSLAND DIRECTORS CONTRIBUTE ON A VOLUNTARY BASIS.

OUR COMMUNITY HELPS US TO SHAPE THE SUPPORT AND SERVICES WE PROVIDE.
OUR PEOPLE

CYSTIC FIBROSIS QUEENSLAND BOARD MEMBERS

<table>
<thead>
<tr>
<th>NAME</th>
<th>POSITION AND APPOINTMENT</th>
</tr>
</thead>
<tbody>
<tr>
<td>Margaret Walker BCom, GAICD</td>
<td>Chair and President 2016</td>
</tr>
<tr>
<td>Petrina Fraccaro BA (Journalism), Dip CS, Grad Cert BA, Grad Dip (PR), MBus (IMC) GAICD</td>
<td>Chief Executive Officer 2016</td>
</tr>
<tr>
<td>Kim Colyer BBus (Acc) CA</td>
<td>Treasurer 2017</td>
</tr>
<tr>
<td>Kirsten Dilena BA (Hons), LB (Hons), Grad Cert BA</td>
<td>Company Secretary 2017</td>
</tr>
<tr>
<td>Lisa Nixon BA MPRIA</td>
<td>Director 2017</td>
</tr>
<tr>
<td>Peter Stewart</td>
<td>Director 2016</td>
</tr>
<tr>
<td>Connie Arundel LLB</td>
<td>Director 2017</td>
</tr>
<tr>
<td>Eamon Dunne BA (Social Work), MA (Health Mgmt) JPQual</td>
<td>Director 2013</td>
</tr>
<tr>
<td>Odette Wiggins BEdu (Primary)</td>
<td>Director 2013</td>
</tr>
<tr>
<td>Ashleigh Beauchamp BBus (Acct), CA, JPQual</td>
<td>Director 2017</td>
</tr>
</tbody>
</table>

CYSTIC FIBROSIS QUEENSLAND TEAM MEMBERS

<table>
<thead>
<tr>
<th>NAME</th>
<th>POSITION</th>
</tr>
</thead>
<tbody>
<tr>
<td>Petrina Fraccaro BA (Journalism), Dip CS, Grad Cert BA, Grad Dip (PR), MBus (IMC) GAICD</td>
<td>Chief Executive Officer</td>
</tr>
<tr>
<td>Courtney Cronin BA</td>
<td>Community Services Coordinator</td>
</tr>
<tr>
<td>Kathleen Jones ADip Court and Parliamentary Reporting, CIV TAE</td>
<td>Community Liaison</td>
</tr>
<tr>
<td>Roz Fenson</td>
<td>Business Development and Marketing</td>
</tr>
<tr>
<td>Gemma Nolan Dip Bus (Mkt), CIV TAE, CIII ECEC, CII CS</td>
<td>Community Engagement and Fundraising</td>
</tr>
<tr>
<td>Tom Betts BA, MA, Grad Dip Edu, Grad Cert Philanthropy and NFP</td>
<td>Grants, Workplace Giving and Bequests</td>
</tr>
<tr>
<td>Louise Booth E.N., Cert IV LL</td>
<td>Regional Bookshop Manager</td>
</tr>
<tr>
<td>Cathy Baker BA, Grad Cert BA</td>
<td>Events Coordinator</td>
</tr>
</tbody>
</table>
THE PERSON LIVING WITH CYSTIC FIBROSIS WAS THE FOCAL POINT OF PRIMARY SUPPORT AND SERVICES.
# CYSTIC FIBROSIS QUEENSLAND MEMBERS

## CYSTIC FIBROSIS QUEENSLAND CONSUMER ADVOCACY NETWORK

<table>
<thead>
<tr>
<th>NAME</th>
<th>POSITION</th>
</tr>
</thead>
<tbody>
<tr>
<td>Petrina Fraccaro</td>
<td>Chief Executive Officer</td>
</tr>
<tr>
<td>Courtney Cronin</td>
<td>Community Services Coordinator</td>
</tr>
<tr>
<td>Kathleen Jones</td>
<td>Community Liaison</td>
</tr>
<tr>
<td>Kylie Holbeck</td>
<td>CF Parent Volunteer</td>
</tr>
<tr>
<td>Connie Arundel</td>
<td>CF Adult and Toowoomba Representative Volunteer</td>
</tr>
<tr>
<td>Leah Mass</td>
<td>CF Parent Volunteer</td>
</tr>
<tr>
<td>Paul McKean</td>
<td>CF Adult Volunteer</td>
</tr>
<tr>
<td>Peter Stewart</td>
<td>CF Adult and Sunshine Coast Representative Volunteer</td>
</tr>
<tr>
<td>Jodie Sutton</td>
<td>CF Parent and Toowoomba Representative Volunteer</td>
</tr>
<tr>
<td>Sonia Marshall</td>
<td>CF Parent and Sunshine Coast Representative Volunteer</td>
</tr>
</tbody>
</table>

## CYSTIC FIBROSIS QUEENSLAND KEY VOLUNTEERS

<table>
<thead>
<tr>
<th>NAME</th>
<th>POSITION</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anne Brehmer</td>
<td>Cystic Fibrosis Queensland Bookshop Volunteer</td>
</tr>
<tr>
<td>Jennifer Sweeney</td>
<td>Cystic Fibrosis Queensland Bookshop Volunteer</td>
</tr>
<tr>
<td>Deb Kong</td>
<td>Cystic Fibrosis Queensland Bookshop Volunteer</td>
</tr>
<tr>
<td>Louen Wright</td>
<td>Cystic Fibrosis Queensland Bookshop Volunteer</td>
</tr>
<tr>
<td>Sarah Hundal</td>
<td>Cystic Fibrosis Queensland Bookshop Volunteer</td>
</tr>
<tr>
<td>Jillian Keane</td>
<td>Cystic Fibrosis Queensland Bookshop Volunteer</td>
</tr>
<tr>
<td>Roslyn Eyles</td>
<td>Cystic Fibrosis Queensland Bookshop Volunteer</td>
</tr>
<tr>
<td>Vicki Payne</td>
<td>Cystic Fibrosis Queensland Bookshop Volunteer</td>
</tr>
<tr>
<td>Michael Doyle</td>
<td>Cystic Fibrosis Queensland Bookshop Volunteer</td>
</tr>
<tr>
<td>Pam Dent</td>
<td>Cystic Fibrosis Queensland Bookshop Volunteer</td>
</tr>
<tr>
<td>Carmen Semf</td>
<td>Cystic Fibrosis Queensland Bookshop Volunteer</td>
</tr>
<tr>
<td>Margaret Douglas</td>
<td>Office Administration, Events and Fundraising Volunteer</td>
</tr>
<tr>
<td>Jim Douglas</td>
<td>Events and Fundraising Volunteer</td>
</tr>
<tr>
<td>Alan Douglas</td>
<td>Events and Fundraising Volunteer</td>
</tr>
<tr>
<td>Charlie Hataraka</td>
<td>Events and Fundraising Volunteer</td>
</tr>
<tr>
<td>Justin Wall</td>
<td>Cystic Fibrosis Adult Keynote Speaker and Advocate</td>
</tr>
<tr>
<td>Kate Rootsey</td>
<td>Cystic Fibrosis Adult Keynote Speaker and Advocate</td>
</tr>
<tr>
<td>Stephen Sadler</td>
<td>Cystic Fibrosis Adult Positive Profile</td>
</tr>
</tbody>
</table>
CYSTIC FIBROSIS QUEENSLAND INTERNSHIPS

<table>
<thead>
<tr>
<th>NAME</th>
<th>UNIVERSITY</th>
</tr>
</thead>
<tbody>
<tr>
<td>Samantha Laws</td>
<td>Queensland University of Technology</td>
</tr>
<tr>
<td>Hannah De Boom</td>
<td>Queensland University of Technology</td>
</tr>
<tr>
<td>Bahnu Gupta</td>
<td>James Cook University</td>
</tr>
<tr>
<td>Ryan Clarke</td>
<td>Griffith University</td>
</tr>
<tr>
<td>Michael Veal</td>
<td>University of Queensland</td>
</tr>
<tr>
<td>Abby Ballard</td>
<td>Queensland University of Technology</td>
</tr>
<tr>
<td>Roberta Wijango</td>
<td>Griffith University</td>
</tr>
<tr>
<td>Ou Lin</td>
<td>Queensland University of Technology</td>
</tr>
<tr>
<td>Anajana Gautam</td>
<td>Queensland University of Technology</td>
</tr>
<tr>
<td>Adam Denaro</td>
<td>Griffith University</td>
</tr>
<tr>
<td>Jaymarin Steele</td>
<td>Griffith University</td>
</tr>
<tr>
<td>Liam Selby</td>
<td>JMC Academy</td>
</tr>
<tr>
<td>Alex Reddington</td>
<td>JMC Academy</td>
</tr>
<tr>
<td>Rebekah Evans</td>
<td>JMC Academy</td>
</tr>
</tbody>
</table>

CYSTIC FIBROSIS QUEENSLAND BOOKSHOP VOLUNTEER CHOIR

<table>
<thead>
<tr>
<th>NAME</th>
<th>POSITION</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tina Shaw</td>
<td>Choir Mistress Volunteer</td>
</tr>
<tr>
<td>Sarah Hundal</td>
<td>Choir Member Volunteer</td>
</tr>
<tr>
<td>Karen Long</td>
<td>Choir Member Volunteer</td>
</tr>
</tbody>
</table>
STRUCTURE AND MANAGEMENT

BOARD

CEO FTE 1

BD AND MARKETING FTE 1

COMMUNITY ENGAGEMENT AND FUNDRAISING FTE 1

GRANTS, REQUESTS AND WORKPLACE GIVING FTE 1

EVENTS FTE 0.2 COMMENCING 2018

INTERNS AND VOLUNTEERS

ASSISTANT COMMENCING 2018 AND TRAINEES FTE 1.6

INTERNS AND VOLUNTEERS

INTERNS AND VOLUNTEERS

ASSISTANT COMMENCING 2018 AND TRAINEES FTE 1.6

INTERNS AND VOLUNTEERS

INTERNS AND VOLUNTEERS

INTERNS AND VOLUNTEERS

INTERNS AND VOLUNTEERS
WHILE THERE IS NO CURE, EXTENSION TO LIFE FOR THOSE LIVING WITH CYSTIC FIBROSIS IS DUE TO BETTER KNOWLEDGE AND IMPROVED UNDERSTANDING OF THE DISEASE.
SECTION 2

SUPPORT AND SERVICES

OUR 2017 SURVEY REACHED OUT TO CYSTIC FIBROSIS ADULTS AND THEIR PARTNERS, PARENTS OF CYSTIC FIBROSIS CHILDREN, CYSTIC FIBROSIS TEENAGERS, AND CYSTIC FIBROSIS CLINICIANS.
HOW WE ARE MAKING A DIFFERENCE

OUR COMMUNITY

Ten years ago, Cystic Fibrosis Queensland supported and advocated for approximately 730 cystic fibrosis sufferers and their families. Today we support almost 1000 sufferers. There is no cure for cystic fibrosis. The increase in the number of people requiring our help is the highest it has ever been and growth is expected. This is because people are living longer today than ever before with cystic fibrosis.

Life extension has come about due to better knowledge and improved understanding of the disease itself. We now know the impact diet, exercise, airway clearance and most importantly, the positive effects infection control has on extending the life of a person living with cystic fibrosis.

We are no longer a charity providing care just for children. More than 52% of people with cystic fibrosis in Australia are adults and we need to continue evolving to provide support and services that reflect their needs.

Our community helps us to shape the support and services we provide. Our 2017 survey reached out to cystic fibrosis adults and their partners, parents of cystic fibrosis children, cystic fibrosis teenagers, and cystic fibrosis clinicians.

Cystic Fibrosis Queensland strives to complement the care and treatment provided by Queensland Health.

65 ROSES PATRON’S MORNING TEA

A highlight in the 65 Roses Month of May calendar is when our Patron, The Governor of Queensland, His Excellency the Honourable Paul de Jersey AC QC and Mrs Kay de Jersey open their home to our Cystic Fibrosis Queensland members, staff, board and volunteers. This event provided an opportunity for all sectors of our community to come together, celebrate achievements and recognise our commitment to our goal - to live lives unaffected by cystic fibrosis.

ROSE COTTAGE

Cystic Fibrosis Queensland owns and maintains a fully furnished, three-bedroom house, Rose Cottage, which offers free
A SERIES OF DINNERS WERE HELD TO ALLOW OUR SERVICES TEAM TO SPEAK DIRECTLY WITH FAMILY MEMBERS WHO ARE SUPPORTING PEOPLE WITH CYSTIC FIBROSIS EVERY DAY.
accommodation to families and partners of people with cystic fibrosis who travel to Brisbane to attend clinics or hospital. Rose Cottage has easy access to transport for all Brisbane hospitals.

Built in the 1960’s, Rose Cottage was a private residence until it was purchased by Cystic Fibrosis Queensland in 1999. The occupancy rate of the cottage is approximately 98%, providing much needed accommodation for our rural, regional and remote families.

To maintain infection control, Rose Cottage cannot accommodate more than one cystic fibrosis sufferer at a time. The need for the accommodation is high and Cystic Fibrosis Queensland is reviewing renovation options for the cottage to accommodate cystic fibrosis sufferers.

Rose Cottage underwent a refurbishment in 2017 to ensure the home-like environment of the cottage remained. The kitchen white goods and appliances were replaced, as were the crockery, bedding and all linen. Air-conditioning was installed in the three bedrooms and pedestal fans supplied. In 2018, it is hoped that we have funds to renovate the bathroom and garden BBQ area.

There is no designated funding for the maintenance and operational costs of Rose Cottage. Volunteers raise funds, and donate their time and energy to ensure Rose Cottage is a home away from home for our members.

EDUCATION

Cystic Fibrosis Queensland educates the broader community about the disease, raising awareness of the chronic illness for advocacy and funding purposes, as well as to alleviate the need for people with cystic fibrosis, and their families to provide explanation.

CF SMART

This free online educational resource provides information for teachers, parents, students and health professionals. The training contributes to professional development for educators.

2017 CYSTIC FIBROSIS QUEENSLAND FORUM AND EXPO

This inaugural event invited clinicians, community workers, support services and equipment manufacturers to speak with our members directly through presentations followed by an expo. Cystic Fibrosis Queensland already has plans in place for the 2018 event.

REGIONAL PARENTS AND PARTNER DINNERS

Family members often travel from rural, regional and remote areas to support their cystic fibrosis family member attend clinics. During this time, they have little to no spare time to engage with Cystic Fibrosis Queensland to learn about the support and services available to alleviate the financial, emotional and psychological burden of living with a chronic illness.

A series of dinners were held to allow our Services Team to speak directly with family members who are supporting people with cystic fibrosis every day. We held events in Cairns, Townsville, Toowoomba, the Gold Coast and the Sunshine Coast. These sessions were not just educational but also met the psychosocial needs of our families.
ACCESS TO VITAL EQUIPMENT

LOAN EQUIPMENT

When cystic fibrosis sufferers’ personal nebulisers are in for repair, or unsuitable to travel with, our members draw on our stock of loan equipment. This is an often called on service by our members and highlights the need to maintain stock in good working order and continually upgrade when finances allow. Current loan stock equipment:

- Oxygen concentrators
- Compressors/nebulisers
- Positive Expiratory Pressure devices

In 2018, we will be adding to our loan equipment stock and have plans in place to purchase additional nebulisers for members to access when traveling, and to upgrade our oxygen concentrators.

SUBSIDIES FOR PERSONAL EQUIPMENT

Due to the cost ($400-$1,000+) for personal compressors and nebulisers, some members rely on loan equipment from Cystic Fibrosis Queensland or their hospital – delaying the purchase of new and/or upgraded models.

Applications for the subsidy to purchase this equipment for use either in the home or for travel is gathering momentum, as families and individuals look to upgrade their aging compressors.

AIRWAY CLEARANCE DEVICES

In addition to subsidies for nebulisers, Cystic Fibrosis Queensland supplements the supply of Queensland Health prescribed airway clearance devices available to the community. This offers our members the opportunity to replace broken equipment, or to be provided with a new or upgraded nebuliser model to better aid their treatment. Devices and locations:

- Mater Young Adults Health Clinic - Lumis NIV machines (mask)
- The Prince Charles Hospital - MyAirvo Machines (humidifiers)
- Lady Cilento Children’s Hospital - IPPB Inhalation Therapy Device

GYM EQUIPMENT

Recovery time during hospital stays is supported by the provision of equipment for hospital gyms. Modern exercise equipment including stationery exercise bikes, treadmills, and weights have been provided to Queensland Health by Cystic Fibrosis Queensland to improve the range of rehabilitative exercises physiotherapists can prescribe to patients. As some of this equipment is easily maneuvered into hospital rooms, isolated patients can stay active within the hygienic confines of their individual rooms. Equipment and location:

- Mater Young Adults Health Clinic - Treadmill and dumbbells
- The Prince Charles Hospital - Recumbent bike (part-funded)

CLEANING SUBSIDIES

Single parent families are the beneficiaries of a home cleaning subsidy. The parent has the freedom to choose their own cleaning professional and book a one-off spring clean of their home, or multiple shorter visits to help maintain a healthy household.

70% OF RESPONDENTS RATE THE SERVICE CYSTIC FIBROSIS QUEENSLAND PROVIDES AS 4 OUT OF 5.
HOW WE ARE MAKING A DIFFERENCE

PHYSICAL ACTIVITY SUBSIDIES

In previous years, physical activity subsidies (PAS) have only been available to cystic fibrosis sufferers when provided by a grant. Daily physical activity is important for airway clearance and helping the immune system remain strong to fight off exacerbations. Due to the critical role exercise plays in the life of a cystic fibrosis sufferer, PAS became available to all members in 2017, with 159 claims received. Subsidies are $150 per year and funded by on-going community fundraising. In addition to PAS, 40 cystic fibrosis families received trampolines, allowing cystic fibrosis children to exercise as part of play.

IN-HOSPITAL PROGRAMS

To ensure cystic fibrosis sufferers reduce both their frequency and duration of hospital stays, it is important for Cystic Fibrosis Queensland to complement hospital programs. Cystic fibrosis affects the pancreas and sufferers struggle to absorb nutrients. Recommendations for those with cystic fibrosis is a diet that includes high calorie food containing fats and salts. Hospitals provide meal plans to ensure that the diet is adhered to, but often sufferers struggle to maintain weight when hospitalised. Cystic Fibrosis Queensland provided the Lady Cilento Children's Hospital with 48 fridges, and the Mater Young Adult Health Clinic with two – one for each room – allowing families to supplement the hospital diet with home cooking. Adults staying at The Prince Charles Hospital receive grocery vouchers, which they can spend on treats and personal items to make their stay that little bit easier.

Boredom Buster Bags are delivered to hospitals weekly. Filled with age and gender appropriate items, these bags help cystic fibrosis children pass time and alleviate the boredom of treatment and hospital stays. Information about available support and services is also included in the bags. In 2017, Cystic Fibrosis Queensland delivered 213 bags.

No matter which hospital a Cystic Fibrosis Queensland member attends, all members are eligible for parking subsidies. Prior to this year, in-hospital programs were covered by grants. To ensure that these services are provided weekly; to all cystic fibrosis members, they are now funded by a combination of grants and on-going community fundraising.

2017 CLIENT SURVEY

The Cystic Fibrosis Queensland Client Survey received 114 responses - 56 parents of children with cystic fibrosis, 33 cystic fibrosis adults, two partners, 13 cystic fibrosis teenagers, and 10 cystic fibrosis clinicians. This survey size provided Cystic Fibrosis Queensland with a 95% accuracy rate that our boarder community would answer in similar terms to the 114 respondents. Survey findings have helped Cystic Fibrosis Queensland model and shape the support and services we need to provide to meet and reflect the needs of our community.

70% of respondents rate the service Cystic Fibrosis Queensland provides as 4 out of 5. On average, Clinicians rated 3.6, adults rated 3.8, parents rated 3.6, teenagers rated 4.33 and partners of cystic fibrosis sufferers rated 4 out of 5.
NO MATTER WHICH HOSPITAL A CYSTIC FIBROSIS QUEENSLAND MEMBER ATTENDS, ALL MEMBERS ARE ELIGIBLE FOR PARKING SUBSIDIES.
### Overview of Support and Services Provided to Our Cystic Fibrosis Queensland Members

<table>
<thead>
<tr>
<th>Service</th>
<th>Adults</th>
<th>Families and Children</th>
</tr>
</thead>
<tbody>
<tr>
<td>Advocacy</td>
<td>•</td>
<td>•</td>
</tr>
<tr>
<td>Career Development Services</td>
<td>•</td>
<td></td>
</tr>
<tr>
<td>CFQ Forum and Expo (annual event)*1</td>
<td>•</td>
<td></td>
</tr>
<tr>
<td>Concessions and Benefits – help with support letters, forms</td>
<td>•</td>
<td>•</td>
</tr>
<tr>
<td>Discounts at CFQ Bookshop</td>
<td>•</td>
<td>•</td>
</tr>
<tr>
<td>Education - CFSmart</td>
<td>•</td>
<td></td>
</tr>
<tr>
<td>Education - tutoring</td>
<td>•</td>
<td>•</td>
</tr>
<tr>
<td>Hospital Parking Subsidy</td>
<td>•</td>
<td></td>
</tr>
<tr>
<td>Hospital Physio Airway Clearance Equipment*2</td>
<td>•</td>
<td></td>
</tr>
<tr>
<td>In-Hospital Program - Boredom Buster Bag</td>
<td>•</td>
<td></td>
</tr>
<tr>
<td>In-Hospital Program - Supermarket Voucher</td>
<td>•</td>
<td></td>
</tr>
<tr>
<td>Loan Equipment</td>
<td>•</td>
<td></td>
</tr>
<tr>
<td>Meetups for Parents and Partners of CF’ers*1</td>
<td>•</td>
<td></td>
</tr>
<tr>
<td>Newly Diagnosed Support</td>
<td></td>
<td>•</td>
</tr>
<tr>
<td>Newsletters</td>
<td>•</td>
<td>•</td>
</tr>
<tr>
<td>No Interest Loan Scheme (NILS)</td>
<td>•</td>
<td>•</td>
</tr>
<tr>
<td>Physical Activities Subsidy</td>
<td>•</td>
<td></td>
</tr>
<tr>
<td>Rose Cottage*1</td>
<td>•</td>
<td></td>
</tr>
<tr>
<td>School Support</td>
<td>•</td>
<td></td>
</tr>
<tr>
<td>Trampolines</td>
<td>•</td>
<td></td>
</tr>
<tr>
<td>Emergency Funding*3</td>
<td>•</td>
<td></td>
</tr>
<tr>
<td>Nebuliser*3</td>
<td>•</td>
<td></td>
</tr>
<tr>
<td>Cleaning*3</td>
<td>•</td>
<td></td>
</tr>
</tbody>
</table>

*1 Infection controls are in place.  
*2 Must be accompanied by a referral from hospital physiotherapist.  
*3 Eligibility specific to Grant.
REVENUE FOR 2017: $1,975,593

GRANTS
- $423,454 (21%)

BOOKSHOP
- $198,036 (10%)

GOVERNMENT
- $229,738 (12%)

FUNDRAISING
- $646,210 (33%)

IN-KIND
- $478,155 (24%)
EXEMPLARY AND EXPENDITURE FOR 2017

EXPENDITURE FOR 2017: $1,975,593

SUPPORT AND SERVICES: $889,353 (45%)
SALARIES: $571,711 (29%)
OPERATIONAL: $466,728 (23%)

PROFIT: $18,480
RESEARCH: $29,321
APPLICATIONS FOR THE NEBULISER SUBSIDY, TO USE EQUIPMENT EITHER IN THE HOME OR FOR TRAVEL, IS GATHERING MOMENTUM.
WE NEED TO CONTINUE EVOLVING TO PROVIDE SUPPORT AND SERVICES THAT REFLECT MEMBERS’ NEEDS.
OVER THE PAST DECADE, THE AUSTRALIAN CYSTIC FIBROSIS RESEARCH TRUST HAS FUNDED MORE THAN $6 000 000.00 OF CYSTIC FIBROSIS RESEARCH.
OUR COMMUNITY PROJECTS

MEETING THE PSYCHOSOCIAL NEEDS OF AN ISOLATING CHRONIC ILLNESS

CF HUB

Justin Wall CF Adult Employee  Paul McKean CF Adult Employee
Kate Roostey CF Adult Employee  Renee Falconer CF Adult Employee

This is an online community created by cystic fibrosis sufferers, for cystic fibrosis sufferers aged 16 years and over. The CF Hub was created to address the issue of social isolation and provide peer-to-peer support. The advice is not medical nor clinical in nature, and is aimed at meeting psychosocial needs only.

This project was made possible due to a LUCRF Community Partnership Trust Grant.


CF CREATIVE SPACE

Justin Wall CF Adult Employee

CF Creative Space is an online place for all people with cystic fibrosis, or those that know someone with cystic fibrosis, to submit their creative wares. People are encouraged to let their creative juices flow!

This project was made possible due to a VERTEX Circle of Care Grant.


CF 4 KIDS

Queensland University of Technology Games Laboratory pro bono and salaried staff
Petrina Fraccaro Chief Executive Officer

An online game based on the early years learning framework to help cystic fibrosis children develop independence and coping skills to manage their chronic illness. The prototype was developed in 2017 and the game will be available by late 2018. This project was made possible due to a VERTEX Circle of Care Grant.
CYSTIC FIBROSIS QUEENSLAND SUPPORTS RESEARCH WHICH WILL BE OF THE GREATEST BENEFIT TO THE MAJORITY OF AUSTRALIANS LIVING WITH CYSTIC FIBROSIS.
OUR COMMUNITY PROJECTS

AUSTRALIAN CYSTIC FIBROSIS RESEARCH TRUST

Over the past decade, the Australian Cystic Fibrosis Research Trust has funded more than $6,000,000.00 of cystic fibrosis research. The Trust is dedicated to funding research into the treatment, and cure of cystic fibrosis, and is committed to including consumers in their research strategy and evaluation process.

In 2017, the Australian Cystic Fibrosis Research Trust launched its revised research strategy and remains committed to the following core objectives:

- Funding research into the treatment and cure of cystic fibrosis
- Improving quality of life outcomes for people with cystic fibrosis
- Attracting the brightest young minds to cystic fibrosis research and funding innovative, even ‘novel’ concepts
- Reducing the fracturing of cystic fibrosis research funds
- Ensuring research is selected on scientific merit and path to impact.

Cystic Fibrosis Queensland has representation on the Board of the Australian Cystic Fibrosis Research Trust and contributes to funding the Innovation Grant program by working collaboratively with Cystic Fibrosis Research Limited.

CYSTIC FIBROSIS RESEARCH LIMITED

Cystic Fibrosis Research Limited is a Trust dedicated to funding research into the treatment and cure of cystic fibrosis. Cystic Fibrosis Queensland has representation on the Board of Cystic Fibrosis Research Limited. Early 2018 will see the Trust fund an Australian Cystic Fibrosis Research Trust Innovation Grant ($80,000.00).

Cystic Fibrosis Queensland works collaboratively with both trusts to ensure funding is provided to leading cystic fibrosis research projects – ensuring we support research which will be of the greatest benefit to the majority of Australians living with cystic fibrosis.
SECTION 3

OUR FINANCES AND FINANCIAL STATEMENTS

EARLY 2018 WILL SEE THE TRUST FUND AN AUSTRALIAN CYSTIC FIBROSIS RESEARCH TRUST INNOVATION GRANT $80 000.00
The Directors present this report on Cystic Fibrosis Queensland Ltd for the financial year ended 31 December 2017.

DIRECTORS

The names of each person who has been a director during the year and to the date of this report are:

Margaret Walker (Chair)
Odette Wiggins
Eamon Dunne
Peter Stewart
Lisa Nixon................................................................................................................................................Appointed 12 March 2017

Kim Colyer (Treasurer) ....................................................................................................................Appointed 12 April 2017

Ashleigh Beauchamp ....................................................................................................................Appointed 12 April 2017

Connie Arundel ....................................................................................................................................Appointed 18 May 2017

Kirsten Dilena (Company Secretary) ............................................................................................Appointed 18 May 2017

Suzy Munt (Treasurer) .....................................................................................................................Resigned 12 April 2017

Roland O’Regan (Company Secretary)..........................................................................................Resigned 18 May 2017

Directors have been in office since the start of the financial year to the date of this report, unless otherwise stated.

PRINCIPAL ACTIVITIES

The principal activity of the company during the financial year was to provide psychosocial support to children, adults and their families, loan equipment, accommodation, subsidies for parking and In-hospital programs; public advocacy; and education programs to the community.

SHORT-TERM AND LONG-TERM OBJECTIVES

The company’s short-term objectives are to:

- Support those people in Queensland and other jurisdictions who are required to access Queensland hospitals due to cystic fibrosis with the goal to live a life not affected by Cystic Fibrosis;
- Support families to meet the needs of a Cystic Fibrosis person in their lives;
- Support community agencies such as childcare centres, schools, workplaces and community physiotherapists to understand the requirements of a person with Cystic Fibrosis;
- Develop fundraising programs to enable the company to meet these goals.

The company’s long-term objectives are to:

- Communicate to current and future clients via a range of mediums to reach people who live throughout Queensland, Northern New South Wales and the Northern Territory. Remain updated with any new developments and directions relating to the management of Cystic Fibrosis;
- Remain sustainable through fundraising efforts and continue to advocate to government for a more equitable ongoing grant.

STRATEGIES

To achieve its state objectives, the company has adopted the following strategies:

- Review operations to drive cost efficiencies, reduce historical debt and consider ongoing sustainability;
- Ensure that staff employed by Cystic Fibrosis Queensland Ltd are appropriately skilled as well as aligned with Cystic Fibrosis Queensland’s vision of ‘lives unaffected by Cystic Fibrosis’.
SUPPORT THOSE PEOPLE IN QUEENSLAND AND OTHER JURISDICTIONS WHO ARE REQUIRED TO ACCESS QUEENSLAND HOSPITALS DUE TO CYSTIC FIBROSIS WITH THE GOAL TO LIVE A LIFE NOT AFFECTED BY CYSTIC FIBROSIS
DIRECTORS’ REPORT

To be relevant and to add value to the cystic fibrosis community as a point of first contact for information about cystic fibrosis in Queensland and the Northern Territory.

To engage in activities that create a better awareness of cystic fibrosis in the community and become better aligned with the national body to affect campaigns that implement real change for the broader cystic fibrosis community.

KEY PERFORMANCE MEASURES

The company measures its own performance through the use of both quantitative and qualitative benchmarks. The benchmarks are used by directors to assess the financial sustainability of the company and whether the company’s short-term and long-term objectives are being achieved.

INFORMATION ON DIRECTORS

MARGARET WALKER | CONTINUING
Qualifications | B Comm. GAICD
Experience
Margaret Walker has recently completed her second term as non executive Director of Defence Housing Australia. She was also Chairman of the Audit Committee and a member of the Nomination and Remuneration Committee. As well as being the Chairman of Cystic Fibrosis Queensland she has recently been appointed a member of the Audit Committee for the Australian Institute of Marine Science. With a strong and extensive background in senior finance executive roles, Margaret brings to any board strong financial, regulatory and risk management experience as well as an informed, practical approach to corporate strategy and program monitoring. Margaret also sits on the Cystic Fibrosis Research Limited Board and the Australian Cystic Fibrosis Research Trust.

ODETTE WIGGINS | CONTINUING
Qualifications | B. Primary Education (NZ)
Experience
Odette has a background in Education and is a parent of a child with cystic fibrosis. She brings a sound understanding of the issues facing both people with cystic fibrosis and the impact this has on families and ongoing schooling.

EAMON DUNNE | CONTINUING
Qualifications | BA (Social Work) MA (Health Management) JP (Qual)
Experience
Community Health Assistant Director—Queensland Health. Eamon Dunne is the Allied Health Facility Leader, Nambour General Hospital. Eamon has an extensive background in Health Management and Social Work. He is well versed in Healthcare Management, Performance Improvement and Project Management. He is also a parent of a cystic fibrosis child.

PETER STEWART | CONTINUING
Experience
Peter is a Resource Planning Manager at Virgin Australia. He brings to the board experience in workforce and capacity operations, planning, strategy and forecasting. As our adult Cystic Fibrosis Queensland Board member, Peter is a critical link in building and maintaining the relationship between our client members and strategic objective of the board. Peter also sits on the Cystic Fibrosis Adult Advisory Committee, The Prince Charles Hospital.

KIM COLYER | APPOINTED 12 APRIL 2017
Qualifications | BBus (Acc) CA
Experience
Kim Colyer has over 19 years’ audit experience and has been a partner at BDO since 2007. She brings in-depth knowledge and experience of general purpose reporting, corporations law and other disclosure requirements to Cystic Fibrosis Queensland. This extensive experience has assisted Kim while working with clients across multiple industries and sectors, particularly Not-For-Profit organisations.
ASHLEIGH BEAUCHAMP | APPOINTED 12 APRIL 2017
Qualifications | BBus (Acct), CA, JPQual
Experience
Ashleigh Beauchamp has over six years' business services experience and has been at BDO since 2012. She brings knowledge and experience of financial reporting, accounting and taxation to Cystic Fibrosis Queensland.

LISA NIXON | APPOINTED 12 MARCH 2017
Qualifications | BA (Journalism), Certified RIMER, Cert AP2.
Experience
Lisa is a highly experienced communications strategist and team leader. With more than 25 years’ experience in corporate communications and media, Lisa’s strength lies in complex problem solving and issues management. She is a sought-after advisor to Boards and Senior Executives on corporate reputation matters, marketing communication team development and strategic communications planning. Lisa has worked at length with public and private sector organisations on campaigns to inform, engage or persuade audiences on a range of matters including healthcare reforms and products, contentious property development issues, new business and product launches and Australian market entry strategies. She has led communications for organisations undergoing change, including mergers, acquisitions, redundancy and insolvency. Her value to clients comes in her ability to comprehend the larger businesses issues and to focus the communications strategic approach to that bigger picture. Lisa also sits on the Cystic Fibrosis Research Limited Board.

CONNIE ARUNDEL | APPOINTED 18 MAY 2017
Qualifications | LLB
Experience
Connie Arundel is a solicitor in commercial/property law and wills and estates at Shine Lawyers. Connie has Cystic Fibrosis and has received a double lung transplant. Connie will bring both youth and experience to the Board as a recipient of medical services over her lifetime. She has a particular interest in ensuring that basic standards are met in health care and have empathy for people who live with the disease.

KIRSTEN DILENA | APPOINTED 18 MAY 2017
Qualifications | BA (Hons), LB (Hons), Grad Cert BA
Experience
Kirsten brings to the board over 15 years in commercial and legal roles specialising in commercial and corporate law, procurement and corporate transactions, governance and compliance and regulatory advice. Kirsten has a background of briefing, advising and sitting on Boards and committees in the government and not-for-profit sectors and brings a combination of commercial and legal governance as well. Kirsten is the Cystic Fibrosis Queensland representative on the Cystic Fibrosis Australia Board.

SUZY MUNT | RESIGNED 12 APRIL 2017
Qualifications | BBus (Acct), CA
Experience
Suzy Munt has over 12 years’ experience in the Chartered Accountant profession working at BDO. With over 4 years in the Not-for-profit and family business sectors, Suzy specialises in taxation, commercial and strategic advice for a diverse range of clients.

ROLAND O’REGAN | RESIGNED 18 MAY 2017
Qualifications | LLB
Experience
Roland is the Partner and Head of the Commercial/Property Law and Dispute Resolution Practice at Kaden Boriss Legal. Roland has a wealth of experience across a wide range of commercial matters, including structure and regulatory advice, corporate transactions, structural set-up and dissolution including complex partnerships and trusts, hospitality law and significant experience in litigation. His skills acquired as a trial advocate and dispute resolution expert, and his background in the commercial and construction arena gives him the knowledge base necessary to assist in finding solutions before matters become disputed.
MEETINGS OF DIRECTORS

During the financial year, nine meetings of directors were held. Attendances by each director were as follows:

<table>
<thead>
<tr>
<th>DIRECTORS' MEETINGS</th>
<th>Number eligible to attend</th>
<th>Number attended</th>
</tr>
</thead>
<tbody>
<tr>
<td>Margaret Walker (Chair)</td>
<td>9</td>
<td>9</td>
</tr>
<tr>
<td>Suzy Munt</td>
<td>3</td>
<td>3</td>
</tr>
<tr>
<td>Odette Wiggins</td>
<td>9</td>
<td>3</td>
</tr>
<tr>
<td>Eamon Dunne</td>
<td>9</td>
<td>6</td>
</tr>
<tr>
<td>Rolan O’Regan</td>
<td>3</td>
<td>1</td>
</tr>
<tr>
<td>Peter Stewart</td>
<td>9</td>
<td>6</td>
</tr>
<tr>
<td>Lisa Nixon</td>
<td>8</td>
<td>5</td>
</tr>
<tr>
<td>Kim Colyer</td>
<td>7</td>
<td>6</td>
</tr>
<tr>
<td>Ashleigh Beauchamp</td>
<td>7</td>
<td>4</td>
</tr>
<tr>
<td>Kirsten Dilena</td>
<td>7</td>
<td>5</td>
</tr>
<tr>
<td>Connie Arundel</td>
<td>6</td>
<td>6</td>
</tr>
</tbody>
</table>

The company is incorporated under the Corporations Act 2001, but now governed by the Australian Charities and Not-for-Profits Commission Act 2012 and is a company limited by guarantee. If the company is wound up, the constitution states that each member is required to contribute a maximum of $100 each towards meeting any outstanding obligations of the company. At 31 December 2017, the total amount that members of the company are liable to contribute if the company is wound up is $22,800 (2016: $2,900).
I AM PLEASED TO PRESENT THE AUDITED FINANCIAL STATEMENTS OF CYSTIC FIBROSIS QUEENSLAND FOR THE YEAR ENDED 31 DECEMBER 2017.
I am pleased to present the audited financial statements of Cystic Fibrosis Queensland for the year ended 31 December 2017.

It’s pleasing to finish the year with a $18 840.00 surplus and a net asset position of $338 377.00. The net surplus has resulted from the ongoing support from major donors and the success of our fundraising activities and events. Total revenues included $478 155 of contributions received in-kind; nil was recorded in the previous year. Thanks to our CEO, Petrina Fracaro, a register for in-kind contributions was maintained for the 2017-year and therefore enabling the company to accurately record contributions received and the corresponding expense/asset, for the first time ever.

Included in trade payables are amounts owing to the ATO in relation to GST. Subsequent to year end, we have successfully entered into a payment plan with the ATO; terms include a first payment of $6 500.00 due 28 March 2018, and monthly payments of $1 500.00 thereafter.

The 2017 year saw significant change in Cystic Fibrosis Queensland’s finance team. During the year, we engaged HLB Mann Judd as our Bookkeeper and as our external auditor. Suzy Munt stepped down as Director and Treasurer in April 2017 and I assumed the role as Treasurer on my appointment to the Board.

Due to the change in auditor during the year, HLB Mann Judd were unable to perform certain audit procedures on the opening balances and therefore this limitation resulted in our audit report being qualified in this respect. The audit report also includes another qualification with respect to the recording of cash donations; this qualification is normal for organisations such as ours.

I’d like to thank Tina Shaw (former Bookkeeper) and Suzy Munt for their contributions to the financial reporting process during their tenure and welcome HLB Mann Judd accounting team.

I look forward to working with HLB Mann Judd, the Cystic Fibrosis Queensland team in another successful year.

Kim Colyer

Treasurer
Cystic Fibrosis Queensland
AUDITOR’S INDEPENDENCE DECLARATION

The lead auditor’s independence declaration for the year ended 31 December 2017 has been received and can be found on page 7 of the financial report.

The directors’ report is signed in accordance with a resolution of the Board of Directors.

M. Walker Director
Date: 15/3/2018

AUDITOR’S INDEPENDENCE DECLARATION

We declare that, to the best of our knowledge and belief, there have been no contraventions of any applicable code of professional conduct in relation to the audit of the financial report of Cystic Fibrosis Queensland Ltd for the year ended 31 December 2017.

HLB Mann Judd
Chartered Accountants
Brisbane, Queensland 15 March 2018

HLB Mann Judd (SE Qld Partnership) ABN 68 929 406 716
Level 15, 89 Eagle Street, Brisbane QLD 4000 | GPO Box 5225 Brisbane QLD 4001
Telephone +61 (07) 3001 8800 | Facsimile +61 (07) 3221 0812 | Email: infoqns@hlbqld.com.au | Website: www.hlb.com.au
Liability limited by a scheme approved under Professional Standards Legislation.

HLB Mann Judd (SE Qld Partnership) is a member of HLB International, a worldwide network of independent accounting firms and business advisers.
## STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME

<table>
<thead>
<tr>
<th>Note</th>
<th>2017</th>
<th>2016</th>
</tr>
</thead>
<tbody>
<tr>
<td>Revenue</td>
<td>1,975,593</td>
<td>1,112,446</td>
</tr>
<tr>
<td>Employee benefits expense</td>
<td>(816,730)</td>
<td>(687,394)</td>
</tr>
<tr>
<td>Depreciation and impairment expense</td>
<td>(27,833)</td>
<td>(86,452)</td>
</tr>
<tr>
<td>Events</td>
<td>(381,600)</td>
<td>(96,752)</td>
</tr>
<tr>
<td>Finance costs</td>
<td>(1,509)</td>
<td>(18,502)</td>
</tr>
<tr>
<td>Fundraising and marketing</td>
<td>(291,341)</td>
<td>(56,625)</td>
</tr>
<tr>
<td>Loss on sale of fixed assets</td>
<td></td>
<td>(3,506)</td>
</tr>
<tr>
<td>Write-down of inventory</td>
<td>(35,032)</td>
<td></td>
</tr>
<tr>
<td>Occupational expenses</td>
<td>(64,949)</td>
<td>(91,225)</td>
</tr>
<tr>
<td>Other operating expenses</td>
<td>(189,835)</td>
<td>(278,299)</td>
</tr>
<tr>
<td>Support services</td>
<td>(148,284)</td>
<td>(117,108)</td>
</tr>
<tr>
<td>Surplus/(deficit) before income tax</td>
<td>18,480</td>
<td>(323,417)</td>
</tr>
<tr>
<td>Income tax expense</td>
<td></td>
<td>(323,417)</td>
</tr>
<tr>
<td>Surplus/(deficit) from continuing operations</td>
<td>18,480</td>
<td>(323,417)</td>
</tr>
<tr>
<td>Surplus/(deficit) for the year</td>
<td>18,480</td>
<td>(323,417)</td>
</tr>
<tr>
<td>Other comprehensive income for the year, net of tax</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total comprehensive income for the year</td>
<td>18,480</td>
<td>(323,417)</td>
</tr>
</tbody>
</table>

### REVIEW OPERATIONS TO DRIVE COST EFFICIENCIES, REDUCE HISTORICAL DEBT AND CONSIDER ONGOING SUSTAINABILITY
# Statement of Financial Position

As at 31 December 2017

<table>
<thead>
<tr>
<th>NOTE</th>
<th>$ 2017</th>
<th>$ 2016</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ASSETS</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Current Assets</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cash and cash equivalents</td>
<td>5</td>
<td>61,857</td>
</tr>
<tr>
<td>Trade and other receivables</td>
<td>6</td>
<td>36,026</td>
</tr>
<tr>
<td>Inventories</td>
<td>7</td>
<td>5,834</td>
</tr>
<tr>
<td>Other assets</td>
<td>8</td>
<td>31,269</td>
</tr>
<tr>
<td><strong>Total Current Assets</strong></td>
<td></td>
<td>134,986</td>
</tr>
<tr>
<td><strong>Non-Current Assets</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Property, plant and equipment</td>
<td>9</td>
<td>446,200</td>
</tr>
<tr>
<td><strong>Total Non-Current Assets</strong></td>
<td></td>
<td>446,200</td>
</tr>
<tr>
<td><strong>TOTAL ASSETS</strong></td>
<td></td>
<td>581,186</td>
</tr>
<tr>
<td><strong>LIABILITIES</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Current Liabilities</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Trade and other payables</td>
<td>10</td>
<td>133,171</td>
</tr>
<tr>
<td>Other financial liabilities</td>
<td>11</td>
<td>1,968</td>
</tr>
<tr>
<td>Employee benefits</td>
<td>12</td>
<td>32,232</td>
</tr>
<tr>
<td>Income received in advance</td>
<td>13</td>
<td>75,438</td>
</tr>
<tr>
<td><strong>Total Current Liabilities</strong></td>
<td></td>
<td>242,809</td>
</tr>
<tr>
<td><strong>Non-Current Liabilities</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>TOTAL LIABILITIES</strong></td>
<td></td>
<td>242,809</td>
</tr>
<tr>
<td><strong>NET ASSETS</strong></td>
<td></td>
<td>338,377</td>
</tr>
<tr>
<td><strong>EQUITY</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Asset Revaluation Reserves</td>
<td>16</td>
<td>139,595</td>
</tr>
<tr>
<td>Retained Earnings/Profit</td>
<td></td>
<td>198,782</td>
</tr>
<tr>
<td><strong>TOTAL EQUITY</strong></td>
<td></td>
<td>338,377</td>
</tr>
</tbody>
</table>
### STATEMENT OF CHANGES IN EQUITY

**FOR THE YEAR ENDED 31 DECEMBER 2017**

<table>
<thead>
<tr>
<th></th>
<th>Retained Earnings $</th>
<th>Asset Revaluation Reserve $</th>
<th>Total $</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>2016</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Balance at 1 January 2016</td>
<td>503,719</td>
<td>139,595</td>
<td>643,314</td>
</tr>
<tr>
<td>Surplus/(deficit)</td>
<td>(323,417)</td>
<td></td>
<td>(323,417)</td>
</tr>
<tr>
<td>Balance at 31 December 2016</td>
<td>180,302</td>
<td>139,595</td>
<td>319,897</td>
</tr>
<tr>
<td><strong>2017</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Balance at 1 January 2017</td>
<td>180,302</td>
<td>139,595</td>
<td>319,897</td>
</tr>
<tr>
<td>Surplus / (deficit)</td>
<td>18,480</td>
<td></td>
<td>18,480</td>
</tr>
<tr>
<td>Balance at 31 December 2017</td>
<td>198,782</td>
<td>139,595</td>
<td>338,377</td>
</tr>
</tbody>
</table>
## STATEMENT OF CASH FLOWS

FOR THE YEAR ENDED 31 DECEMBER 2017

<table>
<thead>
<tr>
<th>CASH FLOW FROM OPERATING ACTIVITIES</th>
<th>NOTE</th>
<th>$ 2017</th>
<th>$ 2016</th>
</tr>
</thead>
<tbody>
<tr>
<td>Receipts from customers</td>
<td></td>
<td>1,361,603</td>
<td>1,147,359</td>
</tr>
<tr>
<td>Payments to suppliers and employees</td>
<td></td>
<td>(1,456,127)</td>
<td>(1,406,212)</td>
</tr>
<tr>
<td>Interest received</td>
<td></td>
<td>115</td>
<td>537</td>
</tr>
<tr>
<td>Interest Paid</td>
<td></td>
<td>(1,509)</td>
<td>(18,502)</td>
</tr>
<tr>
<td>Net cash provided by (used in) operating activities</td>
<td>15b</td>
<td>(95,918)</td>
<td>(276,818)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>CASH FLOW FROM INVESTING ACTIVITIES</th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Disposal of Property, plant and equipment</td>
<td></td>
<td>858,064</td>
<td></td>
</tr>
<tr>
<td>Purchase of Property, plant and equipment</td>
<td></td>
<td>(1,574)</td>
<td>(54,334)</td>
</tr>
<tr>
<td>Net cash used by investing activities</td>
<td></td>
<td>(1,574)</td>
<td>803,730</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>CASH FLOW FROM FINANCING ACTIVITIES</th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Proceeds (repayment) of borrowings</td>
<td></td>
<td>(2,617)</td>
<td>(477,651)</td>
</tr>
<tr>
<td>Net cash used by financing activities</td>
<td></td>
<td>(2,617)</td>
<td>(477,651)</td>
</tr>
<tr>
<td>Net increase (decrease) in cash and cash equivalents held</td>
<td></td>
<td>(100,109)</td>
<td>49,261</td>
</tr>
<tr>
<td>Cash and cash equivalents at beginning of year</td>
<td></td>
<td>161,966</td>
<td>112,705</td>
</tr>
<tr>
<td>Cash and cash equivalents at end of financial year</td>
<td>15a</td>
<td>61,857</td>
<td>161,966</td>
</tr>
</tbody>
</table>

WE NEED TO CONTINUE EVOLVING TO PROVIDE SUPPORT AND SERVICES THAT REFLECT CYSTIC FIBROSIS QUEENSLAND MEMBERS’ NEEDS.
The financial statements cover Cystic Fibrosis Queensland Ltd as an individual company, incorporated and domiciled in Australia. Cystic Fibrosis Queensland Ltd is a company limited by guarantee.

1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

A). BASIS OF PREPARATION

These general purpose financial statements have been prepared in accordance with the Corporations Act 2001 and Australian Accounting Standards—Reduced Disclosure Requirements of the Australian Accounting Standards Board and the Australian Charities and Not-for-Profits Commissions Act 2012. The company is a not-for-profit company for financial reporting purposes under Australian Accounting Standards. Material accounting policies adopted in the preparation of these financial statements are presented below and have been consistently applied unless otherwise stated.

The financial statements, except for the cash flow information, have been prepared on an accrual basis and are based on historical costs, modified, where applicable, by the measurement at fair value of selected non-current assets, financial assets and financial liabilities. The amounts presented in the financial statements have been rounded to the nearest dollar.

B). GOING CONCERN

The entity has a deficiency of net current assets at 31 December 2017 of $107,823 (31 December 2016: $152,562) and operating cash outflows of $95,918 for the year ended 31 December 2017 (2016: $276,818). These conditions give rise to a material uncertainty which may cast significant doubt about the ability of the entity to continue as a going concern.

The ability of the entity to continue as a going concern is principally dependent upon the company’s ability to receive sufficient cash flow proceeds from fundraising, events and grants to meet operational obligations as and when they fall due and payable. In addition, included in current liabilities is an amount of $75,438 (2016: $192,437) relating to grant proceeds received in advance which will be released to income when acquitted and employee benefits provision of $32,232 (2016: $9,817) which is not expected to be fully paid out within twelve months.

As a result of the ongoing support from government departments, the continued support of major donors and the anticipated success of fundraising activities and events, the directors believe the going concern basis of preparation is appropriate, and accordingly have prepared the financial report on this basis. The going concern basis presumes that funds will be available to finance future operations and that the realisation of assets and liabilities will occur in the normal course of business.

Should the entity be unable to continue as a going concern, it may be required to realise its assets and extinguish its liabilities other than in the ordinary course of business, and at amounts that differ from those stated in the financial statements. This financial report does not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts or classification of liabilities and appropriate disclosures that may be necessary should the entity be unable to continue as a going concern.

C). REVENUE

Revenue from the sale of goods is recognised upon the delivery of goods to customers. Grant revenue is recognised in the statement of profit or loss and other comprehensive income when the company obtains control of the grant and it is probable that the economic benefits gained from the grant will flow to the company and the amount of the grant can be measured reliably.

If conditions are attached to the grant which must be satisfied before it is eligible to receive the contribution, the recognition of the grant as revenue will be deferred until those conditions are satisfied.

When grant revenue is received whereby the company incurs an obligation to deliver economic value directly back to the contributor, this is considered a reciprocal transaction and the grant revenue is recognised in the statement of financial position as a liability until the service has been delivered to the contributor, otherwise the grant is recognised as income on receipt.

Cystic Fibrosis Queensland Ltd receives non-reciprocal contributions of assets from the government and other parties for zero or a nominal value. These assets are recognised at fair value on the date of acquisition in the statement of financial position, with a corresponding amount of income recognised in the statement of profit or loss and other comprehensive income.

Donations and bequests are recognised as revenue when the grant is recognised as income on receipt.

Interest revenue is recognised using the effective interest method, which for floating rate financial assets is the rate inherent in the instrument.

Revenue from the rendering of a service is recognised upon the delivery of the service to the customers.

All revenue is stated net of the amount of goods and services tax (GST).
D). INCOME TAX
No provision for income tax has been raised as the company is exempt from income tax under Division 50 of the Income Tax Assessment Act 1997.

E). EMPLOYEE BENEFITS

Short-term employee benefits
Provision is made for the Company’s obligation for short-term employee benefits. Short-term employee benefits are benefits (other than termination benefits) that are expected to be settled wholly within 12 months after the end of the annual reporting period in which the employees render the related service, including wages, salaries and sick leave. Short-term employee benefits are measured at the (undiscounted) amounts expected to be paid when the obligation is settled. The company’s obligations for short-term employee benefits such as wages, salaries and sick leave are recognised as a part of current trade and other payables in the statement of final position.

F). CASH AND CASH EQUIVALENTS
Cash and cash equivalents include cash on hand, deposits held at call with banks, other short term highly liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within short-term borrowings in current liabilities in the statement of financial position.

G). PROPERTY, PLANT AND EQUIPMENT
Each class of property, plant and equipment is carried at cost or fair value as indicated, less, where applicable, accumulated depreciation and any impairment losses.

H). PROPERTY
Freehold land and buildings are shown at their fair value based on periodic, but at least triennial, valuations by external independent valuers, less subsequent depreciation for buildings. The last valuation was performed in 2015.

In periods when the freehold land and buildings are not subject to an independent valuation, the directors conduct directors’ valuations to ensure the carrying amount for the land and buildings is not materially different to the fair value.

Increases in the carrying amount arising on revaluation of land and buildings are recognised in other comprehensive income and accumulated in the revaluation surplus in equity. Revaluation decreases that offset previous increases of the same class of assets shall be recognised in other comprehensive income under the heading of revaluation surplus. All other decreases are recognised in the statement of comprehensive income.

Any accumulated depreciation at the date of the revaluation is eliminated against the gross carrying amount of the asset and the net amount is restated to the revalued amount of the asset.

I). PLANT AND EQUIPMENT
Plant and equipment are measured on the cost basis and are therefore carried at cost less accumulated depreciation and any accumulated impairment losses. In the event the carrying amount of plant and equipment is greater than its estimated recoverable amount, the carrying amount is written down immediately to its estimated recoverable amount and impairment losses are recognised either in profit or loss or as a revaluation decrease if the impairment losses relate to a revalued asset. A formal assessment of recoverable amount is made when impairment indicators are present.

Plant and equipment that have been contributed at no cost, or for nominal cost, are valued and recognised at the fair value of the asset at the date it is acquired.

J). DEPRECIATION
The depreciable amount of all fixed assets, including buildings and capitalised lease assets but excluding freehold land, is depreciated on a straight-line basis or diminishing value basis over the asset’s useful life to the company commencing from the time the asset is held ready for use.

Leasehold improvements are depreciated over the shorter of either the unexpired period of the lease or the estimated useful lives of the improvements. Assets purchased with use of grant funds are fully depreciated in the year of purchase.

The depreciation rates used for each class of depreciable assets are:

- Buildings 4.00% (Straight line)
- Furniture, Fixtures and Fittings 7.00–66.67% (Diminishing value)
- Motor Vehicles 22.50% (Diminishing value)
- Rental Equipment 12.00–50.00% (Diminishing value)

The assets’ residual values and useful lives are reviewed, and adjusted if appropriate, at the end of each reporting period.

K). FINANCIAL INSTRUMENTS

Initial recognition and measurement
Financial assets and financial liabilities are recognised when the company becomes a party to the contractual provisions to the instrument. For financial assets, this is equivalent to the date that the company commits itself to either purchase or sell the asset (i.e. trade date accounting is adopted).

Financial instruments are initially measured at fair value plus transaction costs, except where the instrument is classified “at fair value through profit or loss” in which case transaction costs are recognised immediately as expenses in profit or loss.

Classification and subsequent measurement
Financial instruments are subsequently measured at either of fair value, amortised cost using the effective interest method, or cost. Fair value represents the amount for
which an asset could be exchanged or a liability settled, between knowledgeable, willing parties. Where available, quoted prices in an active market are used to determine fair value. In other circumstances, valuation techniques are adopted.

Amortised cost is calculated:
(a). The amount at which the financial asset or financial liability is measured at initial recognition;
(b). Less principal repayments;
(c). Plus, or minus the cumulative amortisation of the difference, if any, between the amount initially recognised and the maturity amount calculated using the effective interest method; and
(d). Less any reduction for impairment
The effective interest method is used to allocate interest income or interest expense over the relevant period and is equivalent to the rate that exactly discounts estimated future cash payments or receipts (including fees, transaction costs and other premiums or discounts) through the expected life (or when this cannot be reliably predicted, the contractual term) of the financial instrument to the net carrying amount of the financial asset or financial liability. Revisions to expected future net cash flows will necessitate an adjustment to the carrying amount with a consequential recognition of an income or expense item in profit or loss.

The company does not designate any interest as being subject to the requirements of accounting standards specifically applicable to financial instruments.

i. Financial assets at fair value through profit or loss
Financial assets are classified at “fair value through profit or loss” when they are held for trading for the purpose of short-term profit taking, derivatives not held for hedging purposes, or when they are designated as such to avoid an accounting mismatch or to enable performance evaluation where a group of financial assets is managed by key management personnel on a fair value basis in accordance with a documented risk management or investment strategy. Such assets are subsequently measured at fair value with changes in carrying amount being included in profit or loss.

ii. Loans and receivables
Loans and receivables are non-derivative financial assets with fixed or determinable payments that are not quoted in an active market and are subsequently measured at amortised cost.

Loans and receivables are included in current assets, except for those which are not expected to mature within 12 months after the end of the reporting period. (All other loans and receivables are classified as non-current assets.)

iii. Held-to-maturity investments
Held-to-maturity investments are non-derivative financial assets that have fixed maturities and fixed or determinable payments, and it is the company’s intention to hold these investments to maturity. They are subsequently measured at amortised cost.

Held-to-maturity investments are included in non-current assets, except for those which are expected to mature within 12 months at the end of the reporting period. (All other investments are classified as current assets.)

If during the period the company sold or reclassified more than an insignificant amount of the held-to-maturity investments before maturity, the entire held-to-maturity investments category would be tainted and reclassified as available-for-sale.

iv. Available-for-sale financial assets
Available-for-sale investments are non-derivative financial assets that are either not capable of being classified into other categories of financial assets due to their nature or they are designated as such by management. They comprise investments in the equity of other entities where there is neither a fixed maturity nor fixed or determinable payments.

Available-for-sale financial assets are included in non-current assets except for those which are expected to mature within 12 months after the end of the reporting period.

v. Financial liabilities
Non-derivative financial liabilities other than financial guarantees are subsequently measured at amortised cost. Gains or losses are recognised in profit or loss through the amortisation process and when the financial liability is recognised.

vi. Fair Value
Fair value is determined based on current bid prices for all quoted investments. Valuation techniques are applied to determine fair value for all unlisted securities, including recent arm’s length transactions, reference to similar instruments and option pricing models.

vii. Impairment
At the end of each reporting period, the company assesses whether there is objective evidence that a financial asset has been impaired. A financial asset (or a group of financial assets) is deemed to be impaired if, and only if, there is objective evidence of impairment as a result of one or more events (a “loss event”) having occurred, which has an impact on the estimated future cash flows of the financial asset(s).

In the case of available-for-sale financial assets, a significant or prolonged decline in the market value of the instrument is considered to determine whether an impairment has risen. Impairment losses are recognised in the statement of comprehensive income.
L). UNEXPENDED GRANTS/INCOME RECEIVED IN ADVANCE
The company receives grant monies to fund projects either for contracted periods of time or for specific projects irrespective of the period of time required to complete those projects. It is the policy of the company to treat grant monies as unexpended grants in the statement of financial position where the company is contractually obliged to provide the services in a subsequent financial period, or, in the case of specific project grants, where the project has not been completed.

M). GOODS AND SERVICES TAX (GST)
Revenue, expenses and assets are recognised net of the amount of goods and services tax (GST), except where the amount of GST incurred is not recoverable from the Australian Taxation Office (ATO). In these circumstances the GST is recognised as part of the cost of acquisition of the asset or as part of an item of the expense. Receivables and payables in the statement of financial position are shown inclusive of GST.
Cash flows are presented in the statement of cash flows on a gross basis except for the GST component of investing and financing activities, which are disclosed as operating cash flows.

N). COMPARATIVE AMOUNTS
Where required by Accounting Standards, comparative figures have been adjusted to conform with changes in presentation for the current financial year.

O). NEW ACCOUNTING STANDARDS AND INTERPRETATIONS
The AASB has issued a number of new and amended Accounting Standards that have mandatory application dates for future reporting periods, some of which are relevant to the company. The directors have decided not to early adopt any of the new and amended pronouncements. Their assessment of the pronouncements that are relevant to the company but applicable in future reporting periods is set out below:

AASB 9: Financial Instruments and associated Amending Standards (applicable to annual reporting periods beginning on or after 1 January 2018).
The Standard will be applicable retrospectively (subject to the provisions on hedge accounting outlined below) and includes revised requirements for the classification and measurement of financial instruments, revised recognition and derecognition requirements for financial instruments, and simplified requirements for hedge accounting. The key changes that may affect the company on initial application include certain simplifications to the classification of financial assets, simplifications to the accounting of embedded derivatives, upfront accounting for expected credit loss, and the irrevocable election to recognise gains and losses on investments in equity instruments that are not held for trading in other comprehensive income. AASB 9 also introduces a new model for hedge accounting that will allow greater flexibility in the ability to hedge risk, particularly with respect to the hedging of non-financial items. Should the company elect to change its hedge policies in line with the new hedge accounting requirements of the Standard, the application of such accounting would be largely prospective.

Although the directors anticipate that the adoption of AASB 9 may have an impact on the company’s financial instruments, it is impracticable at this stage to provide a reasonable estimate of such impact.

AASB 16: Leases (applicable to annual reporting periods beginning on or after 1 January 2019).
When effective, this Standard will replace the current accounting requirements applicable to leases in AASB 117: Leases and related Interpretations. AASB 16 introduces a single lessee accounting model that eliminates the requirement for leases to be classified as operating or finance leases.
The main changes introduced by the new Standard are as follows:
• Recognition of a right-of-use asset and liability for all leases (excluding short-term leases with less than 12 months of tenure and leases relating to low-value assets);
• Depreciation of right-of-use assets in line with AASB 116: Property, Plant and Equipment in profit or loss and unwinding of the liability in principal and interest components;
• Inclusion of variable lease payments that depend on an index or a rate in the initial measurement of the lease liability using the index or rate at the commencement date;
• Application of a practical expedient to permit a lessee to elect not to separate non lease components and instead account for all components as a lease; and
• Inclusion of additional disclosure requirements.
The transitional provisions of AASB 16 allow a lessee to either retrospectively apply the Standard to comparatives in line with AASB 108: Accounting Policies, Changes in Accounting Estimates and Errors or recognise the cumulative effect of retrospective application as an adjustment to opening equity on the date of initial application.
Although the directors anticipate that the
adoption of AASB 16 will impact the Group’s financial statements, it is impracticable at this stage to provide a reasonable estimate of such impact.

AASB 1058: Income of Not-for-Profit Entities (applicable to annual reporting periods beginning on or after 1 January 2019).

This Standard is applicable to transactions that do not arise from enforceable contracts with customers involving performance obligations. The significant accounting requirements of AASB 1058 are as follows:

- Income arising from an excess of the initial carrying amount of an asset over the related contributions by owners, increases in liabilities, decreases in assets and revenue should be immediately recognised in profit or loss. For this purpose, the assets, liabilities and revenue are to be measured in accordance with other applicable Standards.
- Liabilities should be recognised for the excess of the initial carrying amount of a financial asset (received in a transfer to enable the entity to acquire or construct a recognisable non-financial asset that is to be controlled by the entity) over any related amounts recognised in accordance with the applicable Standards. The liabilities must be amortised to profit or loss as income when the entity satisfies its obligations under the transfer.

An entity may elect to recognise volunteer services or a class of volunteer services as an accounting policy choice if the fair value of those services can be measured reliably, whether or not the services would have been purchased if they had not been donated.

Recognised volunteer services should be measured at fair value and any excess over the related amounts (such as contributions by owners or revenue) immediately recognised as income in profit or loss.

The transitional provisions of this Standard permit an entity to either: restate the contracts that existed in each prior period presented in accordance with AASB 108 (subject to certain practical expedients); or recognise the cumulative effect of retrospective application to incomplete contracts on the date of initial application. For this purpose, a completed contract is a contract or transaction for which the entity has recognised all of the income in accordance with AASB 1004 Contributions. Although the directors anticipate that the adoption of AASB 1058 may have an impact on the company’s financial statements, it is impracticable at this stage to provide a reasonable estimate of such impact.

### 2. CRITICAL ACCOUNTING ESTIMATES AND JUDGEMENTS

**(a). Key Estimates–Employee benefits**

As described in the accounting policies, short-term employee benefits are measured at the (undiscounted) amounts expected to be paid when the obligation is settled.

#### 3. REVENUE AND OTHER INCOME OPERATING ACTIVITIES

<table>
<thead>
<tr>
<th></th>
<th>$2017</th>
<th>$2016</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bookshop/ Thrift shop income</td>
<td>198,036</td>
<td>246,415</td>
</tr>
<tr>
<td>Interest received</td>
<td>115</td>
<td>537</td>
</tr>
<tr>
<td>Queensland health supporting funding</td>
<td>229,738</td>
<td>170,542</td>
</tr>
<tr>
<td>Other grant income</td>
<td>326,906</td>
<td>194,048</td>
</tr>
<tr>
<td>Events income</td>
<td>109,814</td>
<td>115,303</td>
</tr>
<tr>
<td>Fundraising</td>
<td>536,396</td>
<td>369,735</td>
</tr>
<tr>
<td>Other income</td>
<td>96,433</td>
<td>15,866</td>
</tr>
<tr>
<td>Contributions received in-kind</td>
<td>478,155</td>
<td></td>
</tr>
<tr>
<td>Total Revenue</td>
<td>1,975,593</td>
<td>1,112,446</td>
</tr>
</tbody>
</table>

Within the revenues noted above, Cystic Fibrosis Queensland Ltd has received a total of $341,655 (2016: $240,007) in cash donations.
4. RESULT FOR THE YEAR
The result for the year was derived after charging / (crediting) the following items:

<table>
<thead>
<tr>
<th>FINANCE COSTS</th>
<th>$ 2017</th>
<th>$ 2016</th>
</tr>
</thead>
<tbody>
<tr>
<td>Interest–bank</td>
<td>1,509</td>
<td>18,502</td>
</tr>
<tr>
<td>Employee benefits expense</td>
<td>816,730</td>
<td>687,394</td>
</tr>
<tr>
<td>Depreciation and amortisation</td>
<td>27,833</td>
<td>86,452</td>
</tr>
<tr>
<td>Net loss on disposal of property, plant and equipment</td>
<td>3,506</td>
<td></td>
</tr>
<tr>
<td>Occupational expenses</td>
<td>64,949</td>
<td>91,225</td>
</tr>
<tr>
<td>Rental expense on operating leases - Office rent</td>
<td>27,378</td>
<td>55,322</td>
</tr>
</tbody>
</table>

5. CASH AND CASH EQUIVALENTS

<table>
<thead>
<tr>
<th>CASH ON HAND</th>
<th>687</th>
<th>789</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cash on hand</td>
<td>687</td>
<td>789</td>
</tr>
<tr>
<td>Cash at bank</td>
<td>61,170</td>
<td>161,177</td>
</tr>
<tr>
<td>Total</td>
<td>61,857</td>
<td>161,966</td>
</tr>
</tbody>
</table>

6. TRADE AND OTHER RECEIVABLES

<table>
<thead>
<tr>
<th>TRADE RECEIVABLES</th>
<th>$ 2017</th>
<th>$ 2016</th>
</tr>
</thead>
<tbody>
<tr>
<td>Deposits</td>
<td>8,800</td>
<td>9,240</td>
</tr>
<tr>
<td>Incorrect transfer</td>
<td>10,150</td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td>36,026</td>
<td>17,305</td>
</tr>
</tbody>
</table>

7. INVENTORIES

<table>
<thead>
<tr>
<th>Merchandise-at cost</th>
<th>$ 2017</th>
<th>$ 2016</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total</td>
<td>5,834</td>
<td>38,392</td>
</tr>
</tbody>
</table>

8. OTHER ASSETS

| Prepayments | 31,269 | 14,037 |

9. PROPERTY, PLANT AND EQUIPMENT

<table>
<thead>
<tr>
<th>LAND AND BUILDINGS</th>
<th>2017</th>
<th>2016</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rose cottage</td>
<td>485,000</td>
<td>485,000</td>
</tr>
<tr>
<td>At independent valuation</td>
<td>485,000</td>
<td>485,000</td>
</tr>
<tr>
<td>Accumulated depreciation</td>
<td>(38,800)</td>
<td>(18,928)</td>
</tr>
<tr>
<td>Total land and buildings</td>
<td>466,072</td>
<td>446,200</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PLANT AND EQUIPMENT</th>
<th>2017</th>
<th>2016</th>
</tr>
</thead>
<tbody>
<tr>
<td>Furniture, fixtures and fittings at cost</td>
<td>4,761</td>
<td>150,228</td>
</tr>
<tr>
<td>Accumulated depreciation</td>
<td>(4,761)</td>
<td>(143,841)</td>
</tr>
<tr>
<td>Total furniture, fixtures and fittings</td>
<td>6,387</td>
<td></td>
</tr>
<tr>
<td>Rental equipment at cost</td>
<td>90,817</td>
<td>90,817</td>
</tr>
<tr>
<td>Accumulated depreciation</td>
<td>(90,817)</td>
<td>(90,817)</td>
</tr>
<tr>
<td>Total rental equipment</td>
<td>6,387</td>
<td></td>
</tr>
<tr>
<td>Total plant and equipment</td>
<td>446,200</td>
<td>472,459</td>
</tr>
</tbody>
</table>

There were no additions or disposals of assets during the current year. Movement in property, plant and equipment relates to the depreciation and write-off of assets.
10. TRADE AND OTHER PAYABLES

<table>
<thead>
<tr>
<th></th>
<th>$ 2017</th>
<th>$ 2016</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>CURRENT</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Trade payables</td>
<td>121,671</td>
<td>73,782</td>
</tr>
<tr>
<td>PAYG payable</td>
<td>101,743</td>
<td></td>
</tr>
<tr>
<td>Superannuation payable</td>
<td>1,898</td>
<td></td>
</tr>
<tr>
<td>Accrued expenses</td>
<td>11,500</td>
<td></td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td>133,171</td>
<td>177,423</td>
</tr>
</tbody>
</table>

11. OTHER FINANCIAL LIABILITIES

<table>
<thead>
<tr>
<th>UNSECURED LIABILITIES:</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Credit cards</td>
<td>1,968</td>
<td>4,435</td>
</tr>
<tr>
<td>Other loans</td>
<td></td>
<td>150</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td>1,968</td>
<td>4,585</td>
</tr>
</tbody>
</table>

12. EMPLOYEE BENEFITS

<table>
<thead>
<tr>
<th>CURRENT</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Provision for annual leave</td>
<td>32,232</td>
<td>9,817</td>
</tr>
</tbody>
</table>

13. INCOME IN ADVANCE

<table>
<thead>
<tr>
<th>CURRENT</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Deferred income and unexpended grants</td>
<td>75,438</td>
<td>192,437</td>
</tr>
</tbody>
</table>

14. OPERATING LEASE COMMITMENTS

(a). Operating Lease Commitments

<table>
<thead>
<tr>
<th>Payable minimum lease payments:</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Not later than 12 months</td>
<td>85,547</td>
<td>75,707</td>
</tr>
<tr>
<td>Between 12 months and 5 years</td>
<td>97,785</td>
<td>125,333</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td>183,332</td>
<td>201,040</td>
</tr>
</tbody>
</table>

The property lease commitment for Sylvan Road is a non-cancellable operating lease contracted for but not capitalised in the financial statements with lease terms of five years, from November 2016. The property lease commitment for the Nundah Bookshop is also a non-cancellable operating lease contracted for but not capitalised in the financial statements with lease terms of three years, from January 2015.
15. CASH FLOW INFORMATION

(a). Reconciliation of cash
Cash at the end of the financial year as shown in the statement of cash flows is reconciled to items in the statement of financial position as follows:

| Cash and cash equivalents | 61,857 | 161,966 |

(b). Reconciliation of result for the year to cashflows from operating activities

| RECONCILIATION OF NET INCOME TO NET CASH PROVIDED BY OPERATING ACTIVITIES: |
|---------------------------------------------|---------|---------|
| Surplus for the year                       | 18,480  | (323,417) |
| Cash flows excluded from profit attributable to operating activities |         |         |
| Non-cash flows in profit:                  |         |         |
| Depreciation                               | 27,833  | 86,452  |
| Write-down of inventory                    | 32,558  |         |
| Changes in assets and liabilities, net of the effects of purchase |         |         |
| Increase / decrease in trade and other receivables | (18,721) | (14,935) |
| Increase / decrease in prepayments and provisions | (17,232) | (14,037) |
| Increase / decrease in trade and other payables | (44,252) | (5,081) |
| Increase / decrease in unearned revenue    | (116,999) | 49,194 |
| Increase / decrease in employee benefits   | 22,415  | (50,864) |
|                                             | (95,918) | (272,688) |

16. RESERVES
The asset revaluation reserve records revaluations of land and buildings.

17. CAPITAL MANAGEMENT
The entity’s capital consists of financial liabilities supported by financial assets. Management effectively manages the entity’s capital by assessing the entity’s financial risks and responding to changes in these risks and in the market. These responses may include the consideration of debt levels. There have been no changes to the strategy adopted by Management to control the capital of the entity since previous year.

18. KEY MANAGEMENT PERSONNEL DISCLOSURES
The totals of remuneration paid to the key management personnel of Cystic Fibrosis Queensland Ltd during the year are as follows:

| Key management personnel | 152,566 | 165,646 |

19. MEMBERS’ GUARANTEE
The Company is incorporated under the Corporations Act 2001, but now governed by Australian Charities and Not-for-profits Commission Act 2012 and is a Company limited by guarantee. If the Company is wound up, the constitution states that each member is required to contribute a maximum of $100 each towards meeting any outstanding’s and obligations of the Company. At 31 December 2017 the number of members was 228 (2016: 29).
20. REMUNERATION OF AUDITORS

<table>
<thead>
<tr>
<th>REMUNERATION OF THE AUDITOR OF THE COMPANY FOR:</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Audit of the financial statements</td>
<td></td>
</tr>
<tr>
<td>11,500</td>
<td>13,958</td>
</tr>
<tr>
<td>Payment for other non-audit services including:</td>
<td></td>
</tr>
<tr>
<td>Bookkeeping services</td>
<td></td>
</tr>
<tr>
<td>6,720</td>
<td>(50,864)</td>
</tr>
<tr>
<td>Additional accounting services</td>
<td></td>
</tr>
<tr>
<td>3,696</td>
<td>(272,688)</td>
</tr>
<tr>
<td>Review of GST treatments and preparation of BAS</td>
<td></td>
</tr>
<tr>
<td>4,305</td>
<td></td>
</tr>
<tr>
<td>Total cost of other non-audit services</td>
<td></td>
</tr>
<tr>
<td>14,721</td>
<td></td>
</tr>
</tbody>
</table>

21. EVENTS OCCURRING AFTER THE REPORTING DATE

No matters or circumstances have arisen since the end of the financial year which significantly affected or may significantly affect the operations of the Company, the results of those operations, or the state of affairs of the Company in future financial years.

22. FAIR VALUE MEASUREMENT

The company measures its land and buildings at fair value on a recurring basis after initial recognition. The company does not measure any liabilities at fair value on a recurring basis and has no assets or liabilities that are measured at fair value on a non-recurring basis.

For freehold land and buildings, the fair values are based on a directors’ valuation taking into account an external, independent valuation performed in 2015.

23. COMPANY DETAILS

Cystic Fibrosis Queensland Ltd
2/30 Sylvan Road
TOOWONG QLD 4066
CYSTIC FIBROSIS RESEARCH LIMITED IS A TRUST DEDICATED TO FUNDING RESEARCH INTO THE TREATMENT AND CURE OF CYSTIC FIBROSIS.
In accordance with a resolution of the directors of Cystic Fibrosis Queensland Ltd, the directors declare that:
The financial statements and notes, as set out in pages 8 to 22, are in accordance with the Australian Charities and Not-for-Profits Commissions Act 2012 and:
Comply with Australian Accounting Standards—Reduced Disclosure Requirements; and
Give a true and fair view of the financial position of the company as at 31 December 2017 and of its performance during the year ended on that date.
In the directors’ opinion, there are reasonable grounds to believe that the company will be able to pay its debts as and when they become due and payable.
This declaration is signed in accordance with subsection 60.15(2) of the Australian Charities and Not For-Profit Commission Regulation 2013.

M. Walker
Director
TO THE MEMBERS
OF CYSTIC FIBROSIS
QUEENSLAND LTD
QUALIFIED OPINION

We have audited the financial report of Cystic Fibrosis Queensland Ltd (“the Company”) which comprises the statement of financial position as at 31 December 2017, the statement profit or loss and comprehensive income, the statement of changes in equity and the statement of cash flows for the year then ended, and notes to the financial statements, including a summary of significant accounting policies, and the directors’ declaration.

In our opinion, except for the possible effects of the matters described in the Basis for Qualified Opinion paragraph below, the accompanying financial report of the Company is in accordance with Division 60 of the Australian Charities and Not-for-profits Commission Act 2012, including:

Giving a true and fair view of the Company’s financial position as at 31 December 2017 and of its financial performance and cash flows for the year then ended; and

complying with Australian Accounting Standards – Reduced Disclosure Requirements and Division 60 of the Australian Charities and Not-for-profits Commission Regulation 2013.

BASIS FOR QUALIFIED OPINION

The financial report of Cystic Fibrosis Queensland Ltd for the year ended 31 December 2016 was not audited by HLB Mann Judd. We were unable to perform alternative procedures to enable us to form an opinion on the comparative balances as at 31 December 2016. The results of the Company for the year ended 31 December 2017 would be affected to the extent of any misstatements of the 31 December 2016 financial statements. Accordingly, we are not in a position and do not express an opinion on the financial report for the year ended 31 December 2016 which is included for comparative purposes.

Cash donations are a significant source of revenue for Cystic Fibrosis Queensland Ltd. The company has determined that it is impracticable to establish control over the collection of cash donation prior to entry into its financial records. Accordingly, as the evidence available to use regarding this revenue source was limited, our audit procedures with respect to cash donations has been restricted to the amounts recorded in the financial records. We therefore are unable to express an opinion on whether the recorded cash donations of Cystic Fibrosis Queensland Ltd are complete.

We conducted our audit in accordance with Australian Auditing Standards. Our responsibilities under those standards are further described in the Auditor’s Responsibilities for the Audit of the Financial Report section of our report. We are independent of the Company in accordance with the auditor independence requirements of the Accounting Professional and Ethical Standards Board’s APES 110 Code of Ethics for Professional Accountants (“the Code”) that are relevant to our audit of the financial report in Australia. We have also fulfilled our other ethical responsibilities in accordance with the Code.

We confirm that the independence declaration required by Division 60 of the Australian Charities and Not-for-profits Commission Act 2012, which has been given to the Board, would be in the same terms if given as at the time of this auditor’s report.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.
EMPHASIS OF MATTER–GOING CONCERN

We draw attention to Note 1(b) in the financial report, which indicates that Cystic Fibrosis Queensland Ltd has a deficiency of net current assets of $107,823 and operating cash outflows of $95,918 for the year ended 31 December 2017. This condition, along with other matters set out in Note 1, indicate the existence of a material uncertainty that may cast significant doubt as to the company’s ability to continue as a going concern and therefore, the company may be unable to realise its assets and liabilities in the normal course of business. Our opinion is not modified in respect of this matter.

RESPONSIBILITIES OF MANAGEMENT AND THE BOARD FOR THE FINANCIAL REPORT

Management is responsible for the preparation of the financial report that gives a true and fair view in accordance with the Australian Accounting Standards - Reduced Disclosure Requirements and the Australian Charities and Not-for-profits Commission Act 2012 and for such internal control as management determines is necessary to enable the preparation of the financial report that is free from material misstatement, whether due to fraud or error.

In preparing the financial report, management is responsible for assessing the Company’s ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intend to liquidate the Company or to cease operations, or have no realistic alternative but to do so.

The Board is responsible for overseeing the Company’s financial reporting process.

AUDITOR’S RESPONSIBILITIES FOR THE AUDIT OF THE FINANCIAL REPORT

Our objectives are to obtain reasonable assurance about whether the financial report as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor’s report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with Australian Auditing Standards will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this financial report.

As part of an audit in accordance with the Australian Auditing Standards, we exercise professional judgement and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial report, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.

- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control.
INDEPENDENT AUDITOR’S REPORT

- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the management.

- Conclude on the appropriateness of the management’s use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company’s ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor’s report to the related disclosures in the financial report or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor’s report. However, future events or conditions may cause the Company to cease to continue as a going concern.

- Evaluate the overall presentation, structure and content of the financial report, including the disclosures, and whether the financial report represents the underlying transactions and events in a manner that achieves fair presentation.

We communicate with the Board regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide the Board with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

HLB Mann Judd
Chartered Accountants
Brisbane, Queensland 15 March 2018

A B Narayanan
Partner
SECTION 4

SUPPORT OUR CAUSE

PROVIDING SUPPORT, SERVICES AND HOPE TO CYSTIC FIBROSIS SUFFERERS
FUNDRAISING – PARTY WITH A PURPOSE

65 ROSES GALA BALL
Our carnival masquerade-themed 65 Roses Gala Ball took over Brisbane City Hall, 7 October 2017, and we painted the town red. Raising more than $80 000.00 in revenue, with the support of our sponsors we created a vibrant platform for advocacy and business development.

In addition to the revenue raised, we also drew more than $85 000.00 of in-kind support from 12 major charity partners. Our 70 volunteers worked tirelessly on the night ensuring all party goers had the night of their lives.

The celebratory atmosphere and delivery of an emotional program of speeches and films reinforced that we were all there to party with a purpose – to raise funds and awareness for Cystic Fibrosis Queensland.

The crowning glory of the evening was Rachel’s Ring, the diamond and emerald setting valued at over $50 000.00, donated by Rachel’s Aunt in loving memory of her niece Rachel Murphy 1970-1984 who lost her fight to cystic fibrosis.

Cystic Fibrosis Queensland extends thanks and gratitude to:
- Master of Ceremonies, Ian Skippen
- Rio Rhythms
- Jimmy Patch
- Flipside Circus
- JMC Academies
- Pixel Frame

Beyond the revenue and advocacy platform, our 65 Roses Gala Ball provided the business
development team the opportunity to engage with new corporate networks and leads through the presentation of special projects. It displayed our inaugural Queensland-wide 65 Roses Art Prize competition for high schools which saw 44 children paint for a purpose and secured over $25,000.00 worth of funding for our self-sustaining school fundraising program Bounce to Breathe.

**BOUNCE TO BREATHE (B2B)**

B2B is a school community fundraising program that activates a series of pledge challenges to get students engaged and raise funds for cystic fibrosis by bouncing on trampolines. The program supports healthy lifestyle education, with dozens of trampolines located at each activation, and a range of prizes and advanced master class workshops provided.

B2B is only one of the special projects that Cystic Fibrosis Queensland has developed to create standalone innovative initiatives that do not require cause advocacy and that will provide stronger reliable corporate revenue streams. In 2018, we plan to roll out inaugural events such as CEO Kitchen in partnership with TAFE Queensland, the Walking With Legends charity golf classic, and LJ Hooker Rose Cup golf classic.

By the end of 2018, our charity partner brands will reach more than 50,000 homes, and by 2020 we envisage that the programs will have touched the lives of over 300,000 families in Brisbane.

**65 ROSES MONTH OF MAY**

Our 65 Roses Month of May is our major awareness and fundraising campaign for Cystic Fibrosis Queensland. Our dedicated team and volunteers pull out all stops – Queensland-wide – to advocate for our cause and raise much needed funds.

**ADVOCACY**

Queensland Parliamentary Members and Queensland Council members were invited to wear a rose pin on the first parliamentary or council sitting day in May. Cystic Fibrosis Queensland updated them with facts about cystic fibrosis and activities in their electorates or wards to support Queenslanders living with the disease. This successful campaign will be repeated in 2018 and include a request for parliamentarians and councillors to tweet pictures of themselves wearing our rose and supporting our cause.

In Brisbane, Cystic Fibrosis Queensland raised the profile of our cause by illuminating the Story Bridge and Victoria Bridge – both located in the central business district. In 2018, these landmarks will be joined by the illumination of other landmarks, as a show of support, by rural, regional and remote councils in Queensland and the Northern Territory.

**FUNDRAISING**

Our 65 Roses Month of May raised more than $53,000 in revenue to support our cause. This tremendous effort was driven by community engagement. The funds raised contributed to providing our members with physical activity subsidies, hospital parking subsidies, and contributed to the purchase of hospital airway equipment for the Lady Cilento Children’s Hospital, Mater Young Adults Health Centre, and The Prince Charles Hospital.

In 2018, Cystic Fibrosis Queensland will implement a campaign to target 65 community groups and businesses by challenging each entity to raise $650.00 for 65 Roses Month of May.

Cystic Fibrosis Queensland wishes to acknowledge the outstanding efforts achieved by the following 65 Roses Month of May activities (only funds of $500 or greater are listed):
### FUNDRAISING – PARTY WITH A PURPOSE

<table>
<thead>
<tr>
<th>Event Description</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fundraising Services/Collection</td>
<td>$1,899.00</td>
</tr>
<tr>
<td>65kms for Cystic Fibrosis Queensland</td>
<td>$20,328.00</td>
</tr>
<tr>
<td>WMS Collection (Accountants)</td>
<td>$885.00</td>
</tr>
<tr>
<td>11 65 Roses Challenges</td>
<td>$8,200.00</td>
</tr>
<tr>
<td>PPB Rose Sales</td>
<td>$582.00</td>
</tr>
<tr>
<td>Grafton BBQ</td>
<td>$600.00</td>
</tr>
<tr>
<td>Story Bridge Cocktail Event</td>
<td>$2,700.00</td>
</tr>
<tr>
<td>Sofitel Mother’s Day Raffle x4</td>
<td>$780.00</td>
</tr>
<tr>
<td>Mosaic Early Learning Cake Stall</td>
<td>$592.00</td>
</tr>
<tr>
<td>Australian Christian College</td>
<td>$1,021.00</td>
</tr>
<tr>
<td>LKI Community Beats and Eats</td>
<td>$4,758.00</td>
</tr>
<tr>
<td>Rosewood Craft and Quilters</td>
<td>$600.00</td>
</tr>
<tr>
<td>Go Health Club Merchandise</td>
<td>$500.00</td>
</tr>
<tr>
<td>Jodie Sutton - Merchandise</td>
<td>$500.00</td>
</tr>
<tr>
<td>Mango Hill State School</td>
<td>$2,500.00</td>
</tr>
<tr>
<td>Let’s Dance Latin Festival</td>
<td>$2,800.00</td>
</tr>
</tbody>
</table>

Cystic Fibrosis Queensland thanks all individuals, organisations and businesses for contributing to the 2017 65 Roses Campaign and we welcome your support in 2018.
NOOSA TRIATHLON

Cystic Fibrosis Queensland was a proud charity sponsor of the 2017 Noosa Triathlon Multisport festival for the second year running. Team Cystic Fibrosis Queensland consisted of 30 individual triathletes and two teams who actively fundraised for Cystic Fibrosis Queensland as a condition of entry into the triathlon.

Cystic Fibrosis Queensland was present at the pre-event festival, with our team promoting services and fundraising events on the Sunshine Coast, and engaging with the Sunshine Coast community for advocacy. Cystic Fibrosis Queensland was also present curb-side at the triathlon, supporting and cheering on triathletes. Team Cystic Fibrosis Queensland participants raised more than $43,000.00. The funds contributed to providing our members with physical activity subsidies, hospital parking subsidies, and contributed to the purchase of hospital airway equipment for the Lady Cilento Children’s Hospital, Mater Young Adults Health Centre, and The Prince Charles Hospital. In 2018 we will see Team Cystic Fibrosis Queensland enter 50 triathletes to race, raise awareness and funds for our cause.

COMMUNITY FUNDRAISING

Many of our supporters raise funds for Cystic Fibrosis Queensland throughout the year. By building relationships and supporting these third-party fundraisers, Cystic Fibrosis Queensland ensures individuals exceed their targets.

Cystic Fibrosis Queensland wishes to acknowledge the support from the community and make a special mention to the following organisations and individuals.

LJ Hooker Nerang for hosting the LJ Hooker Hunt for a Cure and Gold Coast Great Strides events, and LJ Hooker Forest Lake/Browns Plains for continuing their Great Strides fundraising event.

LKI for developing a ‘Carpark Party’ and continuing their advocacy and fundraising.

Tony ‘Top Hat’ Moroney and his wife Annie for tirelessly dedicating time to collect donations at the Caboolture and Woodford Markets. Their efforts provided 48 fridges to the Lady Cilento Children’s Hospital and two for the Mater Young Adult Health Clinic, as well as 40 trampolines for children with cystic fibrosis.

Cindy Clenton for instilling a tradition of “Crazy Hair Day” and cystic fibrosis awareness over a week of fundraising at Mango Hill State School.

65kms Mums Sonia Marshall, Donna Eaton and Laura Stoll who continue to grow their state wide running event for 65 Roses Month of May.

The inaugural Latin Dance Festival which focused on raising funds for the provision of physical activity subsidies, hospital parking subsidies, airway clearance equipment and massage treatment for Sunshine Coast Cystic Fibrosis Queensland members. Plans are already in place for the 2018 event.
FUNDRAISING – PARTY WITH A PURPOSE

CYSTIC FIBROSIS QUEENSLAND BOOKSHOP

The Cystic Fibrosis Queensland Bookshop has been operational for just over ten years. It is the largest warehouse of quality second-hand books in Queensland. Books are donated by the public and from the Brisbane City Council libraries. The Lord Mayor’s Charitable Trust receives 30% of all former library books sold by the Cystic Fibrosis Queensland Bookshop – our way to demonstrate community-supporting communities.

Volunteers are the backbone of the operation. On any given day, seven days a week there are two to four volunteers rostered to help with stock management, sales and warehousing. Our volunteers come from diverse backgrounds and bring life experience and knowledge to the Cystic Fibrosis Queensland Bookshop and the community it serves. Volunteering hours can be up to 520 hours each month - equating to a saving in salaries of almost $13,000 each month.

In 2017, the Cystic Fibrosis Queensland Bookshop focussed on becoming a social enterprise and building new revenue streams for Cystic Fibrosis Queensland. We achieved this by delivering retail training in partnership with MAX Training, and hosting a work for the dole contract in partnership with Matchworks. The Cystic Fibrosis Queensland Bookshop received government funding to deliver these programs and all work placement took place on our shop floor, adding to our volunteer numbers.

We value our volunteers and are always looking for opportunities to enhance their skills and demonstrate how much we appreciate their work. Government funding allowed for two of the retail training students to join the Cystic Fibrosis Queensland Bookshop as retail trainees. One Work for the Dole participant will also be joining us as a part-time employee in 2018.

The Cystic Fibrosis Queensland Bookshop sought ways to make the environment more welcoming and friendly for its customers this year by introducing a coffee cart and drink machine. This initiative also made a small, positive contribution to revenue.

In alignment with greatly improved accounting practices across the business, the Cystic Fibrosis Queensland Bookshop introduced a point of sale system, providing transparency and accuracy of each sale and donation.

The Cystic Fibrosis Queensland Bookshop also entered discussions with The Lord Mayor’s Charitable Trust to introduce monthly donations in 2018. This will provide a more sustainable way for both organisations to manage cash flow.
Cystic Fibrosis Queensland continues to provide more tomorrows for people living with cystic fibrosis, thanks to the following grant makers, major donors, corporate partners and bequests.

<table>
<thead>
<tr>
<th>GRANT MAKERS, MAJOR DONORS, CORPORATE PARTNERS AND BEQUESTS.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Collier Charitable Fund</td>
</tr>
<tr>
<td>Commonwealth Bank</td>
</tr>
<tr>
<td>Continence Foundation Australia</td>
</tr>
<tr>
<td>Cory Charitable Foundation</td>
</tr>
<tr>
<td>East Leagues</td>
</tr>
<tr>
<td>Felicity's Wish (Donation)</td>
</tr>
<tr>
<td>GCBF</td>
</tr>
<tr>
<td>Honda Foundation</td>
</tr>
<tr>
<td>Inger Rice</td>
</tr>
<tr>
<td>Brisbane Lord Mayor’s Charitable Trust</td>
</tr>
<tr>
<td>Brisbane Lord Mayor’s Suburban Initiative Fund</td>
</tr>
<tr>
<td>Mosaic Foundation</td>
</tr>
<tr>
<td>Queensland Community Foundation</td>
</tr>
<tr>
<td>QLD Mental Health Week</td>
</tr>
<tr>
<td>Vertex Cystic Fibrosis Circle of Care</td>
</tr>
<tr>
<td>Zig Zag Foundation</td>
</tr>
</tbody>
</table>
FUNDRAISING – PARTY WITH A PURPOSE

MAJOR DONORS AND BEQUESTS

Thank you for your generous gift of $1,000.00 or more:

- Australian Water Towers
- Cameron Household
- Firefighting Equipment (Roma)
- Lelliott Household
- Estate of Heather Mary McLeod
- Estate of William A Paige
- White Household
- Evans Household
- Baker Household

RECOGNISING OUR VOLUNTEERS

Cystic Fibrosis Australia Governor General Patron’s Awards

At a ceremony held at Admiralty House Sydney in November, Cystic Fibrosis Australia’s Patron, His Excellency the Honourable Sir Peter Cosgrove AK MC (Retd) Governor-General of Australia, acknowledged the great work and resilience displayed by the cystic fibrosis community. In recognition of their financial and in-kind commitment to Cystic Fibrosis Queensland and Cystic Fibrosis Australia, LJ Hooker (Nerang) jointly received the Corporate Award.

Australia Day 2017 Lilley Award

Cystic Fibrosis Queensland Bookshop volunteer, Pam Dent, was recognised at an Australia Day community ceremony. Pam received her award from the Federal Member for Lilley, the Honourable Wayne Swan MP.

Volunteering week at the Cystic Fibrosis Queensland Bookshop and our volunteer Christmas party

National Volunteer Week is an important date in the Cystic Fibrosis Queensland Bookshop calendar and it is marked by a recognition ceremony and awarding of Cystic Fibrosis Queensland volunteer pins to long-serving volunteers.

Our Christmas celebrations, funded by Brisbane City Council’s Northgate Ward, were a chance to express our gratitude to our volunteers. Local Councillor Adam Allan presented volunteers with gifts.
CYSTIC FIBROSIS QUEENSLAND CONTINUES TO PROVIDE MORE TOMORROWS FOR PEOPLE LIVING WITH CYSTIC FIBROSIS, THANKS TO THE FOLLOWING GRANT MAKERS, MAJOR DONORS, CORPORATE PARTNERS AND BEQUESTS.
Cystic Fibrosis Queensland is looking forward to 2018. Our team of talented and committed staff is focused on creating sustainable income streams to ensure we continue to provide support and services for the increasing number of people living with cystic fibrosis.

Our programs are continually re-evaluated to ensure we are meeting the needs of our changing demographic. Cystic fibrosis is no longer a childhood disease and Cystic Fibrosis Queensland will continue to reflect this change in our service delivery to better meet the needs of the growing number of adults now living with cystic fibrosis.

Relationships with the cystic fibrosis wards at The Lady Cilento Children’s Hospital, Mater Young Adults Health Clinic, and The Prince Charles Hospital remain important to the services we provide. We are an extension of Queensland Health Services and while not funded by government, work tirelessly to complement the clinicians. Cystic Fibrosis Queensland will also continue to reach out to many of the smaller, regional clinics, which provide a crucial service to cystic fibrosis sufferers living some distance from Brisbane.

The importance of adherence to health directives and infection control will remain at the forefront of our advocacy. On behalf of adults with cystic fibrosis, we will continue to advocate for a centre at The Prince Charles Hospital, which meets our Federation 2012 infection control standards. In the meantime, we will work with the clinicians at The Prince Charles Hospital to ensure that to the best of our, and their abilities, adults with cystic fibrosis remain well.

Cystic Fibrosis Queensland is honoured to be the only organisation in Queensland, which represents all cystic fibrosis sufferers, and we will continue the fight to breathe!

CYSTIC FIBROSIS IS NO LONGER A CHILDHOOD DISEASE AND CYSTIC FIBROSIS QUEENSLAND WILL CONTINUE TO REFLECT THIS CHANGE IN OUR SERVICE DELIVERY TO BETTER MEET THE NEEDS OF THE GROWING NUMBER OF ADULTS NOW LIVING WITH CYSTIC FIBROSIS.
OUR MEMBERS WILL CONTINUE TO SHAPE WHO WE ARE.
JULY 2020 WILL BE OUR BIRTHDAY – CELEBRATING 60 YEARS OF PROVIDING SUPPORT, SERVICES AND HOPE TO PEOPLE FIGHTING CYSTIC FIBROSIS.

IMPROVING SERVICE DELIVERY
Results from the 2017 Cystic Fibrosis Queensland Survey shape our business.

Working with Queensland Health to complement Government services – reducing frequency and duration of hospital stays.

RURAL, REGIONAL AND REMOTE
Providing support and services, which all members can access. Continue to develop in-hospital programs, provide subsidies and life-giving equipment. Work with the Federation to promote referral service, education and research initiatives.

CHANGING DEMOGRAPHIC
There are more adults than children living with cystic fibrosis. Our services and support require constant review to meet the needs of the ageing cystic fibrosis population.

PLANNING FOR OUR FUTURE
There is no designated State or Federal Government funding for cystic fibrosis. Need to be a sustainable business with multiple, robust income streams.

ADVOCACY
Continue to be the voice for our community. While there is no cure for cystic fibrosis, education and knowledge about the disease and infection control has greatly improved outcomes.

STAKEHOLDER ENGAGEMENT
Work alongside clinicians, researchers and the State and Territory members of our Federation to ensure that one day we will all lead lives unaffected by cystic fibrosis.
THANK YOU
THANK YOU TO OUR SPONSORS

Dedicated to a better Brisbane

Collier Charitable Fund

Easts

The CORY CHARITABLE Foundation

Inger Rice Foundation

The Honda Foundation

LUCRFsuper

mosaic FOUNDATION

Queensland Community Foundation

Queensland Alliance

Queensland Government

DESIGN BY barbed design
JOIN THE FIGHT TO BREATHE

P +61 7 3359 8000
M +61 412 134 820
www.cysticfibrosis.org.au

FREECALL: 1800 670 990
(Outside Brisbane)